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Calcific aortic valve disease is, by far, the most prevalent 
form of aortic stenosis (AS) worldwide. In the develop-
ing world, AS may also be caused by rheumatic heart 
disease. Calcific aortic valve disease is characterized by 
fibro-calcific remodelling of the valve leaflets. In the 
first phase of the disease, termed aortic sclerosis, 
the valve becomes thickened and mildly calcified but 
these changes do not cause any obstruction to blood 
flow. Over the years, the disease evolves to severe valve 
calcification with impaired leaflet motion and vast blood 
flow obstruction, which are hallmarks of calcific AS1 
(TABLE 1). In developed countries, AS is the third-most 
common cardiovascular disease after coronary artery 
disease and systemic arterial hypertension2. Over the 
past five decades, the management of calcific AS has 
changed dramatically. Doppler echocardiography has 
replaced cardiac catheterization as the method of choice 
for the diagnosis and follow-up of AS, and transcatheter 
valve therapy has emerged as an alternative to surgery for 
aortic valve replacement (AVR). However, no pharma-
cotherapy has proved to reduce either the progression 
of valve stenosis or the resulting adverse effects on left 
ventricular function and patient outcomes. Hence, surgi-
cal or transcatheter AVR are the only effective treatment 
options for severe AS3,4. Overall, this disease is directly 
responsible for approximately 85,000 AVRs and 15,000 
deaths per year in North America2. In this Primer, we 
discuss the epidemiology, mechanisms, diagnosis and 
management of calcific AS, and highlight how the intro-
duction of transcatheter-based valve replacement has 
transformed patient outcomes.
Epidemiology
Calcific AS is the consequence of progressive fibro- 
calcific remodelling occurring on an initially normal 
(tricuspid) aortic valve or a congenitally abnormal 
(bicuspid) aortic valve. Although the prevalence of 
bicuspid aortic valve is only 0.5–1.0% in children, it 
accounts for nearly half of aortic valves that are sur-
gically removed because of calcific AS5. During their 
lifetime, most individuals with a bicuspid aortic valve 
develop some kind of aortic valve pathology, the most 
common being AS5–8. Furthermore, patients with bicus-
pid valve develop calcific AS one or two decades earlier 
than those with a tricuspid valve.
Aortic sclerosis, which is the preclinical phase of 
calcific aortic valve disease, is defined as focal areas 
of valve calcification and leaflet thickening without 
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Abstract | Calcific aortic stenosis (AS) is the most prevalent heart valve disorder in developed 
countries. It is characterized by progressive fibro-calcific remodelling and thickening of the aortic 
valve leaflets that, over years, evolve to cause severe obstruction to cardiac outflow. In developed 
countries, AS is the third-most frequent cardiovascular disease after coronary artery disease and 
systemic arterial hypertension, with a prevalence of 0.4% in the general population and 1.7% in the 
population >65 years old. Congenital abnormality (bicuspid valve) and older age are powerful risk 
factors for calcific AS. Metabolic syndrome and an elevated plasma level of lipoprotein(a) have also 
been associated with increased risk of calcific AS. The pathobiology of calcific AS is complex and 
involves genetic factors, lipoprotein deposition and oxidation, chronic inflammation, osteoblastic 
transition of cardiac valve interstitial cells and active leaflet calcification. Although no 
pharmacotherapy has proved to be effective in reducing the progression of AS, promising therapeutic 
targets include lipoprotein(a), the renin–angiotensin system, receptor activator of NF-κB ligand 
(RANKL; also known as TNFSF11) and ectonucleotidases. Currently, aortic valve replacement (AVR) 
remains the only effective treatment for severe AS. The diagnosis and staging of AS are based on the 
assessment of stenosis severity and left ventricular systolic function by Doppler echocardiography, 
and the presence of symptoms. The introduction of transcatheter AVR in the past decade has been a 
transformative therapeutic innovation for patients at high or prohibitive risk for surgical valve 
replacement, and this new technology might extend to lower-risk patients in the near future.

















significant cardiac blood flow obstruction (aortic jet 
velocity of <2.0 m per s)3. The prevalence of aortic sclero-
sis increases sharply with age. In developed countries, it 
is estimated to be 25% in those >65 years old and almost 
50% in those aged >85 years9–11. According to a recent 
meta-analysis, the rate of progression to AS in individ-
uals with aortic sclerosis is 1.8–1.9% of patients per year11. 
Therefore, the prevalence of calcific AS is much lower 
than that of aortic sclerosis, and has been estimated to be 
0.4% in the general population and 1.7% in the popula-
tion >65 years of age12 in developed countries. There is a 
marked increase in the prevalence of calcific AS in those 
>65 years, as reported by several population-based studies 
in the United States and Europe9,13–15 (FIG. 1). For individ-
uals aged ≥75 years, a pooled analysis of available epi-
demiological data in developed countries produced an 
estimated severe AS prevalence of 3.4% (95% confidence 
interval of 1.1–5.7%), with 75% of those with severe AS 
presenting with symptoms16. The incidence of calcific 
AS has been assessed in a longitudinal Norwegian study 
and was estimated to be 4.9 per 1,000 people per year in a 
population that had a mean age of 60 years at inclusion13. 
The geographical distribution of calcific AS is hetero-
geneous and shows a clustering effect, which is probably 
the consequence of genetic factors17.
Although mitral valve regurgitation has a higher prev-
alence than AS in population-based studies, AS has a 
more important clinical effect18. In the Euro Heart Survey, 
AS was more prevalent than mitral valve regurgitation in 
patients who were referred for in-hospital care and car-
diac surgery18. Furthermore, calcific AS accounted for 
34% of all native (that is, non-prosthetic) valve diseases, 
whereas mitral regurgitation accounted for 25%; and 
calcific AS accounted for 47% of patients operated for 
valvular disease, whereas mitral  regurgitation accounted 
for 14% (REF. 18). 
The burden of calcific AS in the community is 
expected to increase over the next decades owing to 
population ageing and the lack of a prevention strategy 
to reduce disease progression. Estimates based on current 
prevalence rates and demographic forecasts predict that 
the number of patients with calcific AS who are >70 or 
>75 years of age will increase twofold to threefold over 
the next 50 years in developed countries15,16,19.
The epidemiology of AS in developing countries and 
resource-poor settings differs in some respects to that 
seen in developed countries, partly because of the higher 
rates of rheumatic fever and rheumatic heart disease in 
poorer communities. Rheumatic heart disease is a chronic 
condition resulting from acute rheumatic fever, which in 
turn is caused by an untreated throat infection with group 
A Streptococcus. Both rheumatic fever and rheumatic 
heart disease may cause damage to the heart valves and 
can result in stenosis and regurgitation, particularly of the 
mitral and aortic valves. Valvular remodelling markedly 
differs between rheumatic heart disease and calcific AS. 
Fusion of aortic leaflets at commissures is one hallmark 
and distinctive feature of rheumatic heart disease; a dis-
ease that rarely affects the aortic valve alone (less than 
10% of all cases of valvular heart disease in countries in 
which rheumatic fever remains endemic) and most often 
involves the mitral valve. When the aortic valve is affected, 
the dysfunction is often mixed: aortic stenosis combined 
with some degree of aortic regurgitation20,21. The propor-
tion of AS caused by calcific AS is expected to increase in 
industrially developing countries owing to the decreas-
ing incidence of rheumatic fever. In addition, the overall 
burden of calcific AS is expected to increase owing to the 
increase in life expectancy in these regions.
Mechanisms/pathophysiology
For a long time, calcific aortic valve disease was thought to 
be a ‘degenerative’ process caused by time-dependent wear 
and tear of the leaflets and passive calcium deposition. 
There are now compelling histopathological and clinical 
data suggesting that calcific valve disease is, in fact, an 
active and multifaceted condition involving lipoprotein 
deposition, chronic inflammation, osteoblastic transition 
of valve interstitial cells and active leaflet calcification22,23.
Aortic valve anatomy and remodelling
The aortic valve is typically composed of three leaflets that 
are named according to their location with respect to the 
coronary artery; specifically, the left coronary, right coro-
nary and non-coronary leaflets (FIG. 2). Each leaflet has a 
trilaminar structure that determines the biomechanical 
properties of the aortic valve24. The outermost layers of 
the leaflet are formed by the fibrosa and ventricularis, 
which face the aorta and the left ventricular outflow tract, 
respectively. The spongiosa, which has a high proteoglycan 
content, is located between the fibrosa and ventricularis 
(FIG. 3). The fibrosa is rich in circumferentially oriented 
collagen type I and III fibres25, whereas in the ventricularis, 
radially oriented elastic fibres predominate. The ventricu-
laris composition provides compliance (that is, the ability 
to expand under pressure) and allows the apposition of 
free edge regions of leaflets, thus preventing the back-
wards flow of blood into the left ventricle during diastole. 
The cellular population of these aortic valve layers includes 
valve interstitial cells (VICs), smooth muscle cells (SMCs; 
<5% of the population) and endothelial cells. The endothe-
lial cells cover the aortic and ventricular surface and there-
fore provide an interface between the blood and the aortic 
valve26. VICs are the predominant cells in the aortic valve, 
whereas SMCs reside at the base of the ventricularis27.
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Inspection of surgically explanted valves with calcific 
AS reveals two features, fibrosis and calcification (FIG. 3), 
which substantially alter the biomechanical properties of 
the aortic valve leaflets. A small proportion (10–15%) of 
calcific AS valves show advanced osteogenic metaplasia 
with the presence of osteoblast-like cells, chondrocytes 
and bone marrow28. Calcified valves often contain dense 
inflammatory infiltrates, which mostly consist of mac-
rophages29,30. Mineralization starts in the fibrosa layer 
and is often localized in the vicinity of lipid deposits. 
Together, these observations suggest that the fibro- 
calcific process in the aortic valve is a response to injury, 
which might be triggered by lipid-derived species and 
inflammation31 (FIG. 4).
In addition, excess production and disorganization 
of collagen fibres is an important feature of calcific AS. 
Fibrosis increases the stiffness of the aortic valve and 
might play a considerable part in promoting mineral-
ization. To this effect, the collagen produced by VICs 
functions as a scaffold on which the nucleation of 
calcium and phosphorus can start32. Serum-induced 
mineralization of collagen is increased in vitro by a 
popu lation of VICs that have a pro-calcifying phenotype 
with elevated alkaline phosphatase (ALP) expression33,34. 
Furthermore, the increased production of several com-
ponents of the extracellular matrix, including periostin, 
tenascin (also known as tenascin C) and proteoglycans 
contributes to the remodelling of the aortic valve dur-
ing AS35,36. The exact role of non-collagenous proteins 
in the pathophysiology of AS is still mostly unknown, 
but growing evidence indicates that complex inter-
actions between extracellular matrix proteins and cells 
provide crucial signals during normal reparative and 
 pathological processes in the aortic valve37.
Lipids
Lipid infiltration and oxidation. Increasing evidence 
suggests that infiltration of the aortic valve by lipo-
proteins has a central role in promoting inflammation, 
which precedes the pathological mineralization that is 
characteristic of calcific AS38. Therefore, the retention 
of lipids promotes a chronic low-grade inflammatory 




At risk of AS NA • Bicuspid aortic valve (or other congenital valve anomaly) or aortic valve 
sclerosis
• No obstruction to blood flow
• No symptoms
• Clinical and echocardiographic 
follow‑up every 3–5 years
• No indication of AVR
Mild or 
moderate AS
NA • Mild-to-moderate leaflet calcification of a bicuspid valve or tricuspid valve 
with some reduction in systolic motion
• Mild or moderate AS‡
• Early left ventricular diastolic dysfunction might be present but normal LVEF
• No symptoms
• Clinical and echocardiographic 
follow‑up every 3–5 years for 
mild AS and every 1–2 years for 
moderate AS
• No indication of AVR
Severe AS Asymptomatic 




• Severe leaflet calcification or congenital stenosis with a severely reduced 
leaflet opening
• Severe AS‡
• Left ventricular diastolic dysfunction but normal LVEF
• No symptoms
• Clinical and echocardiographic 
follow‑up every 6–12 months
• Indication of AVR (class IIa) if 
stenosis is very severe‡ and low 
surgical risk
Asymptomatic 




• Severe leaflet calcification or congenital stenosis with a severely reduced 
leaflet opening
• Severe AS‡
• LVEF of <50%
• No symptoms





• Severe leaflet calcification or congenital stenosis with a severely reduced 
leaflet opening
• Severe AS with high gradient‡
• Left ventricular diastolic dysfunction, impaired left ventricular longitudinal 
systolic function and pulmonary hypertension may be present
• Symptoms include exertional dyspnoea, angina, syncope or pre-syncope and 
decreased exercise tolerance




severe AS with 
preserved LVEF
• Severe leaflet calcification or congenital stenosis with a severely reduced 
leaflet opening
• Severe AS with low gradient‡
• Small left ventricular cavity with pronounced concentric remodelling, 
restrictive diastolic filling, and low-flow but normal LVEF
• Symptoms include heart failure, angina, syncope or pre-syncope




severe AS with 
reduced LVEF
• Severe leaflet calcification or congenital stenosis with a severely reduced 
leaflet opening
• Severe AS with low gradient‡
• Left ventricular diastolic dysfunction and LVEF of <50%
• Symptoms include heart failure, angina, syncope or pre-syncope
• Indication of AVR (class IIa or 
class IIb if no left ventricular 
flow reserve)
AS, aortic stenosis; AVR, aortic valve replacement; LVEF, left ventricular ejection fraction; NA, not applicable. *Indication of AVR: for class I AVR should be carried 
out; for class IIa AVR is reasonable; and for class IIb AVR may be considered. ‡See TABLE 2 for definitions.
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process that, in turn, might induce an osteogenic pro-
gram in aortic valves. In this regard, histological studies 
have shown that several apolipoproteins (apos), such as 
apoB, apoE, apoA1 and apo(a), are present in surgically 
removed stenotic aortic valves39.
Oxidative stress has also been implicated in calcific AS. 
For instance, immunostaining has shown that apoB colo-
calizes with oxidized low-density lipoproteins (Ox-LDLs) 
in valves from patients with calcific AS40,41, and that there 
is an association between the level of Ox-LDL and the 
degree of inflammation and fibro-calcific remodelling 
in surgically removed AS valves40,42. Oxidative stress is 
increased in AS valves and is at least partly related to 
the uncoupling of the nitric oxide synthase (NOS) path-
way43. In addition, the expression NAD(P)H oxidase is 
increased in surgically explanted calcific AS valves and 
contributes to the production of reactive oxygen spe-
cies (ROS)44. Therefore, the production of peroxide and 
superoxide anions in the vicinity of calcified areas might 
participate in the production of oxidatively modified 
lipid species with osteogenic properties43. Work carried 
out in vitro has shown that Ox-LDL and several oxidized 
phospholipid (Ox-PL) species promote the calcification 
of isolated vascular cells45. Circulating Ox-PLs are mostly 
carried in vivo by lipoprotein(a) (Lp(a))46, which is an 
LDL-like particle in which the apoB protein is linked by 
a disulphide bridge to apo(a)47. Recent studies that used 
a Mendelian randomization design showed that the gene 
encoding apo(a) (LPA) is potentially causally related to 
calcific aortic valve disease48–50. In addition, Capoulade 
and colleagues showed that circulating Lp(a) and Ox-PL 
levels were independently associated with faster progres-
sion of calcific AS51. Together, these studies suggest that 
high circulating levels of Lp(a) might promote the accu-
mulation of Ox-PLs in the aortic valve, which could, in 
turn, trigger an osteogenic response (FIG. 4).
Lipid retention and enzymatically modified lipid 
species. Proteoglycans such as biglycan and decorin are 
overexpressed in aortic valves during calcific AS and 
might actively participate in lipid retention and mod-
ification52–54 (FIG. 4). Moreover, transforming growth 
factor β1 (TGFβ1), which is activated in calcific AS, has 
been shown to promote the elongation of glycosamino-
glycan (GAG) chains55. In turn, GAG chain elongation 
increases the interaction between proteoglycans and 
lipoproteins55. The accumulation and retention of lipo-
proteins in the aortic valve is a crucial event as lipids 
might be used by different enzymes to produce bioactive 
lipid-derived compounds, such as lysophospholipids56.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) 
levels are increased in stenotic aortic valves and this 
increase is associated with fibro-calcific remodelling57,58 
(FIG. 4). Circulating levels of Lp-PLA2 are also positively 
and independently related to the progression of calcific 
AS59. Lp-PLA2 is transported by apoB-containing lipo-
proteins and is enriched in small, dense LDL and Lp(a)60. 
Lp-PLA2 transforms Ox-PLs into lysophosphatidylcho-
line (lysoPC), which promotes the loss of mitochondrial 
membrane potential and apoptosis of VICs57,61. In addi-
tion, Bouchareb and colleagues62 recently showed that 
ectonucleotide pyrophosphatase/phosphodiesterase fam-
ily member 2 (ENPP2; also known as autotaxin), a lyso-
phospholipase D, is probably transported into the aortic 
valve by Lp(a) and is also secreted by VICs in response to 
diverse stimuli, including tumour necrosis factor (TNF; 
also known as TNFα)62. Autotaxin transforms lysoPC 
into lysophosphatidic acid (lysoPA). Of interest, in vitro 
knockdown of autotaxin prevents the mineralization of 
VICs induced by lysoPC, which suggests that lysoPA is 
probably the mediator that promotes osteogenic pro-
gramming in VICs. To this effect, in a mouse model, 
the administration of lysoPA increased the deposition 
of hydroxyapatite (a form of calcium apatite) in the aor-
tic valve and accelerated the development of calcific AS. 
Therefore, it is possible that autotaxin and lysoPA are key 
factors that explain the link between Lp(a) and AS63.
In addition to lysophospholipids, the arachidonic 
acid pathway, which produces leukotrienes and prosta-
glandins, has been shown to play a considerable part 
in the mineralization of the aortic valve64 (FIG. 4). For 
instance, the expression of 5-lipoxygenase, which is 
required for leukotriene synthesis, is increased in aortic 
valves during calcific AS, and leukotriene C4 promotes 
the expression of bone morphogenetic protein 2 (BMP2) 
and BMP6 as well as the mineralization of VICs in cul-
ture64. A recent study showed that prostaglandin G/H 
synthase 2 (PTGS2; also known as cyclooxygenase 2 
(COX2)) is expressed by VICs isolated from AS valves65. 
In support of a role for COX2 in calcific AS, loss of func-
tion of Cox2 in klotho-deficient mice, which develop 

















Lindroos et al. Stewart et al. Nkomo et al.
85
Eveborn et al. Danielsen et al.
Figure 1 | The prevalence of AS as a function of age. 
The prevalence of aortic stenosis (AS) according to age in 
the following population-based series from the USA or 
Europe: Lindroos et al. (Finland)14, in which AS was defined 
as an aortic valve area of <1.2 cm²; Stewart et al. 
(Cardiovascular Health Study, USA)9, in which AS was 
defined as a peak aortic jet velocity of >2.5 m per s; 
Nkomo et al. (USA)12, in which AS was defined as an aortic 
valve area of <1.5 cm2; Eveborn et al. (Tromsø Study, 
Norway)13, in which AS was defined as a mean gradient of 
≥15 mm Hg; and Danielsen et al. (AGES-Reykjavik Study, 
Iceland)15, in which AS was defined as an indexed aortic 
valve area of ≤0.6 cm² per m².
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calcification of the aortic valve amongst other features, 
reduced the mineralization of the aortic valve65. Taken 
together, these findings suggest that several processes 
promote the retention of lipids in the aortic valve and 
produce bioactive lipid species, which in turn promote 
inflammation and mineralization of aortic valve leaflets.
Inflammation
Tissue remodelling and neovascularization. Fibro-
calcific remodelling and inflammation of the aortic 
valve are intricately linked processes with important 
crosstalk. Inflammatory infiltrate in mineralized aortic 
valves that have been removed surgically is composed of 
macrophages, mast cells, CD4+ T cells and CD8+ T cells66. 
Several oxidized lipid species might activate the innate 
immune response through Toll-like receptors (TLRs) 
and the nuclear factor-κB (NF-κB) pathway. TLRs are 
also expressed by VICs (in the case of TLR2 and TLR4) 
and may promote an osteogenic phenotype in isolated 
VICs67,68. Conversely, the role of adaptive immunity in 
calcific AS is still mostly unknown, but studies have 
shown that a subset of memory T cells is activated during 
AS and that clonal expansion of a T cell receptor reper-
toire is present in surgically removed calcific AS valves69. 
These data suggest that both innate and adaptive immune 
responses are probably involved in the pathobiology of 
calcific AS.
A histopathological study carried out on 285 aortic 
valves from patients with calcific AS showed that the pres-
ence of dense, chronic inflammatory infiltrates was related 
to the remodelling score of the leaflets and to the presence 
of neovascularization29. Although the exact role of neo-
vascularization in driving AS is still mostly unknown, it 
is possible that it is involved in the recruitment of inflam-
matory and osteoprogenitor cells (FIG. 4). In support of this 
hypothesis, mice that are deficient in chondromodulin 1 
(encoded by Lect1), which is an anti-angiogenic factor, 
have thickened and mineralized aortic valve leaflets70. 
Aged (22 months) Lect1−/− mice develop capillary-like 
structures in their aortic valve leaflets, and this is accom-
panied by the presence of inflammatory cells and lipid 
deposits70. In human stenotic aortic valves, CD34+ 
endothelial progenitor cells, which participate in new 
vessel formation, have been observed in clusters in close 
proximity to SPARC (also called osteonectin) and matrix 
metalloproteinase 9 (MMP9)71. SPARC is a matricellular 
protein expressed by VICs during calcification that is 
cleaved by MMPs into peptides with angiogenic activity71. 
Several MMPs, including MMP2, MMP9 and MMP12, 
are overexpressed in human calcific AS valve tissue72. 
As  such, angiogenic SPARC peptides might promote neo-
vascularization by CD34+ endothelial progenitor cells and 
might cause inflammation as well as remodelling of the 
aortic valve. In addition, cathepsins K, V and S, which are 
proteases that can degrade extracellular matrix proteins, 
are expressed and activated during AS73, and in ApoE−/− 
mice, cathepsin S has been shown to promote elastolysis 
and mineralization of the aortic valve74. Therefore, inflam-
mation and neovascularization are linked to remodelling 
and mineralization of the aortic valve.













Figure 2 | Comparison of tricuspid and bicuspid aortic valve structures. Schematic representation of a normal — 
tricuspid — aortic valve with the three cusps (part a), a bicuspid valve with right non-coronary cusp fusion and one raphe 
(the line of union between the fused cups) (part b), a bicuspid valve with fusion of the right and left coronary cusps and no 
raphe (part c), a bicuspid valve with right–left coronary cusp fusion and one raphe (part d), and a bicuspid valve with fusion 
of the left and non-coronary cups and one raphe (part e). LC, left coronary; LCA, left coronary artery; NC, non-coronary; 
RC, right coronary; RCA, right coronary artery.
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Cytokines. TNF is secreted by monocytes and macro-
phages, and activates TNF receptor superfamily member 
1A (TNFR1). TNFR1 activation results in activation of 
NF-κB and its downstream targets, including IL-1β and 
IL-6) (REFS 75–78) (FIG. 4). These cytokines promote the 
mineralization of VICs and activate an osteogenic pro-
gramme, which may involve the expression of homeobox 
protein MSX2 (REFS 75–78). To this effect, treatment of 
adventitial fibroblasts with TNF increased the expression 
of MSX2 through the production of ROS79. Mice that are 
deficient in IL-1 receptor antagonist protein (IL-1RN; 
encoded by Il1rn) have higher plasma levels of TNF than 
wild-type mice and develop a thickening of the aortic 
valve78. However, Il1rn−/−Tnf−/− mice are protected and do 
not develop a thickening of the aortic valve, which sug-
gests that TNF plays an important part in promoting the 
remodelling of the aortic valve. In humans, the expres-
sion of TNF ligand superfamily member 10 (TNF10; 
also known as TRAIL), which is a member of the TNF-
related cytokines, is increased in calcific AS valves and 
promotes the  mineralization of VIC cultures through 
death  receptor 4 (REF. 80).
IL-6, another cytokine with pleiotropic activities, has 
been implicated in calcific AS. IL-6 is increased in human 
calcified stenotic valves and is secreted in large amounts 
by cultured human VICs when they are treated with an 
osteogenic medium81. In addition, knockdown of IL6 sub-
stantially reduces the expression of BMP2 and the mineral-
ization of VIC cultures81. Moreover, although it has not yet 
been investigated in VICs, IL-6 induces the expression of 
receptor activator of NF-κB ligand (RANKL; also known as 
TNFSF11) in bone cells, which activates its cognate recep-
tor RANK (also known as TNFRSF11A)82. Overexpression 
of RANKL during calcific AS might have an important role 
in pathogenesis, as secreted RANKL activates VICs to pro-
duce extracellular matrix83 (FIG. 4). In support of this role, 
the administration of osteoprotegerin (OPG; also known 
as TNFRSF11b), which is a decoy receptor for RANKL, to 
low-density lipoprotein receptor knockout (Ldlr−/−) mice 
decreased calcification and the expression of osteogenic 
genes in aortic valves84. Of interest, in bone, RANKL is 
expressed by osteoblasts and promotes the resorption 
of mineral by osteoclasts. Therefore, it is possible that a 
dysregulation of RANKL–RANK–OPG explains the link 
between osteoporosis and vascular and valvular calcifi-
cation66. In this regard, several epidemiological studies 
have underlined an association between  osteoporosis and 
 vascular and/or valvular calcification66,85–87.
Angiotensin II
Angiotensin-converting enzyme (ACE) and chymase are 
overexpressed in calcific AS valves and are involved in 
the production of angiotensin II88,89 (FIG. 4). Chymase is 
secreted by mast cells present in calcific AS valve tissues 
and converts angiotensin I into angiotensin II88. In addi-
tion, patients with calcific AS have elevated blood plasma 
levels of angiotensin II, which correlates with the valvular 
expression of TNF and IL-6 (REF. 90). Angiotensin II is 
a potent activator of the NF-κB pathway and promotes 
a strong fibrotic response in isolated cells. In mice, the 
administration of angiotensin II promotes fibrosis of the 
aortic valve91. Moreover, in a rabbit model of hypercholes-
terolaemia, the administration of olmesartan, which is an 
angiotensin receptor blocker (ARB), prevents the thick-
ening of the aortic valve that normally develops in these 
rabbits92. Retrospective non-randomized studies have 
reported that administration of ARBs, but not ACE inhib-
itors, is associated with less fibro-calcific remodelling of 
aortic valve leaflets and slower progression of valve steno-
sis93,94. Therefore, it is possible that a substantial amount of 
angiotensin II is produced by chymase in the aortic valve, 
the effect of which is blocked downstream by ARBs but 
not by ACE inhibitors.
Mineralization
Osteogenic differentiation. The endothelium that covers 
the healthy aortic valve expresses several anti- osteogenic 
genes in a spatially distributed manner95. The endothe-
lium that covers the aortic side of leaflets shows less 
expression of anti-osteogenic genes compared with the 
endothelium on the ventricular side. For instance, aortic- 
side endothelium expresses lower levels of chordin and 
OPG, which are negative regulators of BMP2, BMP4 
and RANKL. A potential explanation for this difference 
in expression could be shear stress. Oscillatory shear 
stress has been shown to modulate the expression of 
~1,000 genes and ~30 microRNAs (miRNAs) in human 
primary cultures of aortic valve endothelial cells96. For 
instance, the expression of miRNA-187, which promotes 
cell growth and proliferation, was increased when these 
cultures were exposed to oscillatory shear. Endothelial 
cells covering the fibrosa (facing the aorta) are exposed 
to low oscillatory shear stress compared with cells facing 
the left ventricle. Although the functional relevance of 
these findings remains to be fully investigated, shear stress 
might at least partly explain why the fibro-calcific process 
 predominantly occurs in the fibrosa layer.








Figure 3 | Macroscopic and histopathological appearance of normal and abnormal 
aortic valves. Photographs of a normal aortic valve (part a) and an aortic valve with 
severe calcific aortic stenosis (AS) (part b). Histopathological section of a normal aortic 
valve with haematoxylin staining showing the trilaminar structure of the valve from top 
to bottom (part c). Histopathological section of a valve with severe calcific AS with 
haematoxylin staining showing the presence of fibrotic material and a calcified nodule. 
The tissue is thickened by the excess of fibrotic material, and the calcified nodule, 
located in the fibrosa, contributes to alter the normal architecture of the leaflet (part d).
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In human stenotic aortic valves, several osteogenic 
genes are overexpressed72, whereas others show altered 
function that can affect their role in signalling path-
ways. For instance, Garg and colleagues97 showed that 
mutations in NOTCH1 were associated with bicuspid 
aortic valves, which are prone to developing calcific 
AS97. Notch family of receptors are involved in cell fate 
determination. The activation of NOTCH1 in VICs 
leads to the formation of the Notch intracellular domain 
(NICD) fragment, which associates with the recombin-
ing binding protein suppressor of hairless (RBPJ) in the 
nucleus, where it promotes the expression of the hairy 
repressors. The hairy repressors prevent the expres-
sion of the osteogenic factors BMP2 and runt-related 
Leukotrienes
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Figure 4 | Pathogenesis of calcific AS. Endothelial damage allows infiltration 
of lipids, specifically low-density lipoprotein (LDL) and lipoprotein(a) (Lp(a)) 
into the fibrosa and triggers the recruitment of inflammatory cells into the 
aortic valve. Endothelial injury can be triggered by several factors including 
lipid-derived species, cytokines, mechanical stress and radiation injury. 
The production of reactive oxygen species (ROS) is promoted by the 
uncoupling of nitric oxide synthase (NOS), which increases the oxidation of 
lipids and further intensifies the secretion of cytokines. Enzymes transported 
in the aortic valve by lipoproteins (that is, LDL and Lp(a)) such as 
lipoprotein-associated phospholipase A2 (Lp-PLA2) and ectonucleotide 
pyrophosphatase/phosphodiesterase 2 (ENPP2; also known as autotaxin 
(ATX)) produce lysophospholipid derivatives. ATX, which is also secreted by 
valve interstitial cells (VICs), transforms lysophosphatidylcholine (lysoPC) 
into lysophosphatidic acid (lysoPA). Several factors including lysoPA, the 
receptor activator of nuclear factor-κB ligand (RANKL; also known as 
TNFSF11) and WNT3a promote the osteogenic transition of VICs. 
Arachidonic acid (AA) generated by cytosolic PLA2 promotes the production 
of eicosanoids (for example, prostaglandins and leukotrienes) through 
prostaglandin G/H synthase 2 (PTGS2; also known as COX2) and 
5‑lipoxygenase (5‑LO) pathways, respectively. In turn, eicosanoids promote 
inflammation and mineralization. Chymase and angiotensin-converting 
enzyme (ACE) promote the production of angiotensin II, which incr ases the 
synthesis and secretion of collagen by VICs. Owing to increased production 
of matrix metalloproteinases (MMPs) and decreased synthesis of tissue 
inhibitors of metalloproteinases (TIMPs), disorganized fibrous tissue 
accumulates within the aortic valve. Microcalcification begins early in the 
disease, driven by microvesicles secreted by VICs and macrophages. 
In addition, overexpression of ectonucleotidases (ENPP1, 5ʹ-nucleotidase 
ecto (NT5E)) and alkaline phosphatase (ALP)) promotes both apoptosis and 
osteogenic-mediated mineralization. Bone morphogenetic protein 2 (BMP2) 
leads to osteogenic transdifferentiation, which is associated with the 
expression of bone-related transcription factors (for example, runt-related 
transcription factor 2 (RUNX2) and homeobox protein MSX2). 
Osteoblast‑like cells subsequently coordinate calcification of the aortic valve 
as part of a highly regulated process analogous to skeletal bone formation. 
Deposition of mineralized matrix is accompanied by fibrosis and 
neovascularization, which is abetted by vascular endothelial growth factor 
(VEGF). In turn, neovascularization increases the recruitment of 
inflammatory cells and bone marrow-derived osteoprogenitor cells. 
A2AR, adenosine A2A receptor; sPLA2, secreted PLA2; LPAR, lysophosphatidic 
acid receptor; Ox‑PL, oxidized phospholipid; Ox‑LDL, oxidized LDL; 
TGFβ, transforming growth factor-β; TNF, tumour necrosis factor.
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transcription factor 2 (RUNX2) in VICs98, suggesting 
that VICs are driven towards an osteogenic differentia-
tion pathway in calcific AS. To this effect, heterozygous 
Notch1+/− and Rbpj+/− mice develop mineralization of 
the aortic valve99. In addition, the NICD interferes in 
the nucleus with β-catenin (also known as catenin β1), 
a downstream effector of the WNT pathway, which is 
also a key driver of osteogenic differentiation100. A recent 
study in endothelial cells showed that NOTCH1 regu-
lates the expression of more than a 1,000 genes involved 
in inflammation and osteogenesis by altering the epi-
genetic signature at enhancer regions101. Moreover, in 
human stenotic aortic valves, WNT3a, an agonist of 
the WNT pathway, is overexpressed102. The activation 
of a co-receptor formed by LDLR-related protein 5 
and G protein-coupled Frizzled receptors, which are 
expressed by VICs, leads to the stabilization of β-catenin 
and to osteogenic differentiation102 (FIG. 4). In vascular 
cells, BMP2 promotes the expression of MSX2, a pos-
itive regulator of the WNT pathway103. Several factors, 
including inflammatory cytokines and oxidized lipid 
derivatives, have been shown to induce the expression 
of BMP2 in different cell types, including VICs104.
Recent studies have also highlighted that the expres-
sion of several miRNAs is dysregulated in AS and this 
might affect the osteogenic programming of VICs. 
In this regard, miRNA-30b, which is decreased in min-
eralized aortic valves, is a negative regulator of RUNX2 
(REF. 105). Hence, a dysfunction of Notch and WNT path-
ways as well as a dysregulation of miRNAs contribute to 
increased pro-osteogenic signals in VICs.
Mineral deposition. Osteogenic reprograming of VICs 
brings about a series of events that promote the depo-
sition of a calcified matrix. The mechanism (or mech-
anisms) by which VICs mineralizes the extracellular 
matrix is still poorly defined but recent observational 
and experimental work suggests that cells secrete small 
vesicles rich in ectonucleotidases that promote the 
nucleation of calcium and phosphorus106,107. A build-up 
of phosphate in calcifying vesicles, which also contain 
the annexin V–S100A9 complex that binds calcium, 
promotes the nucleation of minerals108. Secretion of 
calcifying vesicles has classically been attributed to 
cells that transdifferentiate into osteoblast-like cells, in 
which case calcification proceeds with the deposition 
of well- organized bone-like mineral matrix (known as 
hydroxyapatite of calcium)109. However, programmed 
cell death leads to the production of apoptotic bodies 
with similar properties to calcifying vesicles. Apoptosis 
of VICs is promoted by different stimuli including 
cytokines, ROS and altered purinergic signalling. 
Apoptotic bodies function as nidi for dystrophic calci-
fication, a form of mineralization that consists of amor-
phous deposits of calcium and phosphorus crystals. 
In human aortic valves, it is likely that both osteogenic 
and apoptotic processes contribute to the mineralization 
process, and at least partly rely on ectonucleotidases110. 
In support of this involvement, several ectonucleotidases, 
such as ALP, ENPP1 and  5ʹ- nucleotidase (5ʹ-NT; also 
known as CD73), are overexpressed in human stenotic 
aortic valves110–112 (FIG. 4). These membrane-bound 
enzymes use nucleotides and nucleosides secreted by 
cells as substrates and produce phosphate-derived prod-
ucts that promote mineralization112. For instance, ENPP1 
hydrolyses ATP into AMP and pyrophosphate, which is 
a strong inhibitor of mineralization. Conversely, ALP has 
a broad range of substrates, including the mineralization 
inhibitor pyrophosphate from which it produces phos-
phate with strong pro-mineralizing activity. Moreover, 
the overactivity of ENPP1 and 5ʹ-NT in human stenotic 
aortic valves depletes extracellular ATP and produces 
adenosine with osteogenic activity111. A decrease in 
the level of extracellular ATP also diminishes puriner-
gic signalling through the P2Y purinoceptor 2 (P2Y2). 
In VICs, P2Y2 prevents the mineralization of cells by 
interfering with apoptosis and also by promoting the 
activation of carbonic anhydrase 12 (CA12)110,113. CA12 
in VICs is normally expressed at the cell membrane fol-
lowing activation of P2Y2 and promotes the acidification 
of the extracellular space leading to resorption of min-
eral deposits113. As such, purinergic signalling, which is 
under the control of ectonucleotidases, plays a central 
part in controlling the mineralization of the aortic valve.
In summary, studies carried out in the past several 
years have shown that oxidation and infiltration of the 
aortic valve by lipids generate several bioactive lipid spe-
cies that trigger inflammation of the aortic valve. The 
activation of several pathways with multiple points of 
crosstalk disrupts the normal biology of the aortic valve 
and promotes fibro-calcific remodelling.
Pathophysiology of left ventricular dysfunction
The symptoms in AS are essentially due to an imbalance 
between the increase in left ventricular haemodynamic 
load caused by valvular obstruction, on the one hand, 
and the capacity of the left ventricle to overcome this 
increase in load both at rest and during exercise, on the 
other hand. AS results in increased left ventricular sys-
tolic pressure that leads to hypertrophy of the cardiomy-
ocytes and interstitial fibrosis (FIG. 5). The mechanical 
signal generated by increased left ventricular systolic 
pressure initiates a cascade of biological events, includ-
ing re-expression of immature fetal genes, which leads to 
coordinated cardiac growth in patients with AS114. This 
increase in cardiac mass is due to the hypertrophy of 
existing myocytes rather than to hyperplasia, because 
cardiomyocytes become terminally differentiated soon 
after birth. The concurrent addition of sarcomeres 
(force-generating units) causes an increase in myocyte 
width, which in turn increases wall thickness and there-
fore contributes to normalization of left ventricular wall 
stress and maintenance of left ventricular ejection per-
formance despite elevated systolic pressure. To support 
the increased biomechanical load, the myocyte growth 
must be accompanied by coordinated increases in the 
surrounding architecture of connective tissue as well as 
the capillary and nerve networks114. This ‘reactive’ inter-
stitial fibrosis that results from the increase in collagen 
synthesis by myofibroblasts in response to pressure over-
load has a diffuse distribution within the interstitium 
and might be, at least partly, reversible following AVR115.
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The pattern of the left ventricular adaptive response 
to pressure overload in AS is highly heterogeneous and 
includes concentric remodelling, concentric hyper-
trophy and eccentric hypertrophy (FIG. 6). The pattern 
and magnitude of left ventricular hypertrophic remod-
elling is influenced not only by AS severity but also by 
several other factors, including age, sex, genetic factors, 
metabolic factors and the coexistence of coronary artery 
disease or hypertension116–119. Among individuals with 
the same degree of AS, women tend to develop concen-
tric remodelling or concentric hypertrophy most often, 
whereas men are more prone than women to develop-
ing eccentric hypertrophy116. In patients with calcific 
AS, left ventricular concentric remodelling or hypertro-
phy has been linked to worse myocardial function and 
increased risk of cardiac events and mortality compared 
with patients with normal left ventricular geometry or 
with left ventricular eccentric hypertrophy120–122. Obesity, 
metabolic syndrome and diabetes also predispose an 
individual to the development of more concentric 
 hypertrophy in the presence of AS117,118.
The left ventricular hypertrophy that leads to a 
reduced density of coronary arteriolar vessels, and the 
increased left ventricular transmural pressures that 
lead to increased coronary vascular resistance, result 
in the reduction of coronary flow reserve in patients 
with AS123,124. The reduction of coronary flow reserve 
limits the ability of the coronary circulation to increase 
flow to match myocardial oxygen demand, especially 
during exercise, and it is therefore a key factor in the 
development of myocardial ischaemia and the occur-
rence of symptoms. Repetitive myocardial ischaemia 
related to the exhaustion of coronary flow reserve leads 
to apoptosis of myocytes and to the development of 
‘replacement’ myocardial fibrosis. This type of fibrosis 
occurs predominantly in the subendocardial and mid-
wall layers of the left ventricle wall and is generally not 
reversible following relief of left ventricular pressure 
overload by AVR. The impairment of coronary flow 
reserve might also explain why patients with severe AS 
can present with angina symptoms despite having angio-
graphically normal coronary arteries, and why these 
symptoms might regress immediately after AVR125.
Left ventricular diastolic dysfunction occurs early 
in the disease course and worsens with progression of 
stenosis severity and myocardial fibrosis (FIG. 5). In the 
more advanced stages of the disease, the increased left 
ventricular filling pressures lead to secondary pulmo-
nary hypertension and dyspnoea symptoms126,127. The 
global left ventricular systolic function, which is meas-
ured using the left ventricular ejection fraction (LVEF), 
and cardiac output are generally well preserved even in 
the presence of severe AS, because the increase in left 
ventricular wall thickness allows wall stress to remain 
relatively normal. Reduced LVEF or cardiac output 
occurs only in end-stage disease and is usually preceded 
by clinical symptoms. However, a large proportion of 
patients with preserved LVEF have subtle left ventricular 
systolic dysfunction that is characterized by impaired left 
ventricular longitudinal function with relatively well pre-
served radial and circumferential function (BOX 1). The 
left ventricular myocardial wall is composed of three lay-
ers from the inside to the outside of the left ventricle: the 
subendocardial layer that surrounds the left ventricular 
cavity, the mid-wall layer and the subepicardial layer. 
In pressure overload cardiomyopathies, there is an early 
Figure 5 | Maladaptive remodelling and impaired function of the left ventricle in response to pressure overload 
from AS. The narrowing of the aortic valve orifice causes an acceleration of the blood flow velocity with a concomitant 
decrease in systolic blood pressure between the left ventricular outflow tract (LVOT) and the aorta. The increased left 
ventricular pressure imposed by AS results in left ventricular hypertrophy (augmentation of the left ventricular myocardial 
mass), reduced coronary flow reserve, myocardial fibrosis, diastolic dysfunction and decreased longitudinal systolic 
shortening, although the ejection fraction remains normal in most patients. Left atrial enlargement is common owing to 
elevated left ventricular filling pressures, which often lead to secondary pulmonary hypertension and right ventricular 
dysfunction in the more advanced stages of the disease.
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and selective alteration of the shortening of myocardial 
fibres within the subendocardial layer in which ischae-
mia and fibrosis are generally more pronounced128–130 
(FIG. 5). The fibres in this layer are oriented longitudinally 
(compared with circumferentially in the mid-wall layer), 
which explains the selective alteration of the left ven-
tricular longitudinal function in these patients. Hence, 
a considerable proportion of patients with AS may have 
subclinical left ventricular systolic dysfunction despite 
preserved LVEF and the absence of symptoms.
Diagnosis, screening and prevention
Risk factors and prevention
Although some clinical and genetic risk factors have 
been associated with the onset and progression of 
calcific AS, no strategy has so far been proved to be 
efficient for primary or secondary prevention of this 
disease. Calcific AS shares several risk factors with cor-
onary artery disease but it also presents some important 
distinctive features.
Clinical risk factors. Congenital leaflet abnormality 
and older age are both powerful risk factors for devel-
oping calcific AS. For instance, the lifetime risk of 
AVR is approximately 50% in individuals with a bicus-
pid valve. Bicuspid aortic valves have two functional 
leaflets often of unequal size. This abnormality results 
from incomplete separation of commissures during 
embryonic development8. Although leaflet orientation 
varies among patients, the most common form con-
sists of a fusion of the right and left coronary leaflets (in 
~60% of patients), followed by fusion between the right 
and the non- coronary leaflets (in ~35% of patients), and 
fusion between left and non-coronary cusp (in ~5% of 
patients)131 (FIG. 2). A bicuspid aortic valve is associated 
with an increased risk of aortopathy, in which genetic, 
haemodynamic and mechanical factors might participate 
in the mineralization of the aortic valve132. In individuals 
with a bicuspid valve and in those with a tricuspid valve, 
age is a powerful risk factor for AS9,133. The other clinical 
risk factors associated with AS are similar to those associ-
ated with atherosclerosis and include male sex, smoking, 
hypertension, hypercholesterolaemia, obesity, metabolic 
 syndrome, diabetes and elevated Lp(a)9,48,134–136.
In patients with AS, the rate of stenosis progres-
sion over time varies substantially from one patient to 
another. The clinical factors associated with faster steno-
sis progression include older age, severity of the stenosis 
and the degree of aortic valve calcification at diagnosis, 
smoking, hypertension, obesity, metabolic syndrome, 
secondary hyperparathyroidism, renal failure, ele-
vated circulating levels of Lp(a) and increased activity 
of Lp-PLA2 (REFS 51,59,94,137–142). In particular, the 
presence of elevated plasma Lp(a) (>50 mg per dl; the 
upper normal limit is 30 mg per dl) is associated with a 
twofold faster stenosis progression51.
In addition, hypertension, and particularly systolic 
hypertension, is highly prevalent in these patients, affect-
ing 30–70% of those with AS94,143,144. Recent studies sug-
gest that hypertension accelerates the progression of AS, 
potentially owing to increased mechanical stress on the 
valve leaflets and activation of the renin–angiotensin 
system (as discussed above)94. Moreover, hypertension 
further increases the left ventricular afterload (BOX 1) 
that is already elevated in patients with AS and contrib-
utes to the risk of developing symptoms and adverse 
cardiac events94,144.
Genetic risk factors. Several studies suggest that a genetic 
component is involved in promoting calcific AS associ-
ated with bicuspid or tricuspid aortic valves6,17,48,145. 
However, despite the evidence of a strong inheritance 
pattern for some cases of bicuspid aortic valve with 
an incomplete penetrance, the genetic architecture of 
calcific AS is still poorly understood145. So far, variants 
of NOTCH1 and GATA-binding protein 5 (GATA5) 
have been associated with bicuspid aortic valves in 
humans97,146,147. NOTCH1 mutations explain approxi-
mately 4% of sporadic cases of AS that occur in the con-
text of a bicuspid aortic valve148,149. As discussed above, 
some mutations in NOTCH1 that affect its function 
might promote aortic valve mineralization. Therefore, it 
is possible that gene variants that predispose individuals 
to developing a bicuspid aortic valve also promote valve 
mineralization later in life, thus further exacerbating the 
risk of developing calcific AS. A recent genome-wide 
association study found that variants located in RUNX2 
Figure 6 | Patterns of left ventricular remodelling. Four left ventricular remodelling 
patterns can be defined according to the left ventricular mass and the ratio of the left 
ventricular mass to the left ventricular cavity size: for normal pattern both left ventricular 
mass and mass/cavity ratio are normal; for concentric remodelling the left ventricular 
mass is normal but the mass/cavity ratio is increased (thick left ventricular walls with 
small cavity); for concentric hypertrophy both left ventricular mass and mass/cavity ratio 
are increased; and for eccentric remodelling left ventricular mass is increased but the 
mass/cavity ratio is normal (thickness of left ventricular walls is normal or slightly 
increased and the left ventricular cavity is enlarged). Figure is reproduced from REF. 267, 
Nature Publishing Group. 
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and calcium channel voltage-dependent L-type alpha 
1C subunit (CACNA1C), which encode an osteogenic 
transcription factor and a voltage-dependent calcium 
channel subunit, respectively, were associated with cal-
cific AS and were found to upregulate their respective 
mRNA levels150. Also, studies using a candidate gene 
approach have linked several gene variants with calcific 
AS. Although variants of vitamin D receptor (VDR), 
APOE, APOB, IL10, NOTCH1 and ENPP1 have been 
found to be significantly associated with AS, these stud-
ies suffer from small sample size and require replication 
in larger series6.
A large study using a Mendelian randomization 
design identified the single-nucleotide polymorphism 
(SNP) rs10455872 in the LPA gene as the only genome-
wide significant SNP associated with the presence 
of aortic valve calcification and clinical calcific AS48. 
Subsequent studies have validated these findings and 
have also reported an association between elevated 
Lp(a) plasma levels and the prevalence of calcific AS, 
and the need for AVR in the general population49–51. 
The presence of the rs10455872 allele is associated with 
a 1.5–2.0-fold increase in the risk of incident calcific 
AS48–50. When considered in light of the clinical and basic 
research findings on Lp(a) discussed above, lowering of 
Lp(a)  seems to be a promising novel target for the treat-
ment of this disease, particularly to prevent disease pro-
gression. However, further studies are needed to evaluate 
the role of Lp(a) in AS in more detail.
A second study using a Mendelian randomization 
design reported a strong association between genetic 
predisposition to elevated LDL cholesterol, as measured 
by weighted genetic risk scores, and the presence of aortic 
valve calcification and incident cases of calcific AS151. 
However, three randomized clinical trials failed to show 
any significant benefit of lowering LDL using statins on 
the progression of AS152–154. Therefore, it is possible that 
elevated LDL cholesterol promotes the initiation of cal-
cific aortic valve disease but has minimal or no effect on 
AS progression. Moreover, the protective effect of statin 
therapy in AS might be counterbalanced by its off- target 
effects, including pro-osteogenic properties, worsening 
of insulin resistance and increased Lp(a) levels51,141. 
Whether other lipid-lowering strategies (for instance, 
proprotein convertase subtilisin/kexin-type 9 (PCSK9) 
inhibitors) would prevent or slow AS progression is 
unknown and this question needs to be addressed. 
In summary, no pharmacotherapy has proved to be 
 effective in reducing the progression of AS.
Diagnosis
Diagnosis of AS is generally established using an echo-
cardiographic examination, which provides a wealth 
of information regarding heart valve anatomy and 
blood flow parameters155 (FIG. 7). The same techniques 
can be used for the diagnosis of calcific AS and rheu-
matic AS. In the vast majority of patients, referral to 
echocardio graphy is motivated by the auscultation of a 
systolic murmur and/or the development of symptoms 
including dyspnoea, angina, syncope and dizziness. 
In some cases, AS is first recognized on echocardio-
graphy requested for other indications. Although most 
patients are diagnosed long before the onset of symp-
toms and are followed prospectively on a regular basis 
until AVR is indicated, a small proportion (5–10%) 
of patients are not diagnosed with AS until late in the 
disease course when they present with symptoms of 
heart failure156. The identification of the presence and 
stage of AS includes the assessment of the aortic valve 
Box 1 | Key measurements and tools used for AS assessment
• Aortic valve area (AVA): surface of the aortic valve orifice. It can be measured by 
Doppler echocardiography, left heart catheterization or cardiac magnetic resonance.
• Aortic valve calcium density: aortic valve calcium score measured by CT divided by 
the cross-sectional area of the aortic annulus measured by echocardiography or CT. 
It is expressed in Agatston units per cm2.
• Carotid upstroke: the pulse pressure of the carotid artery that can be assessed at the 
level of the neck is characterized by a smooth, fairly rapid upstroke and a smooth, 
more gradual downstroke. In patients with severe aortic stenosis, the carotid upstroke 
is delayed.
• Circumferential function: circumferential contraction of the left ventricular wall that 
is mainly driven by the myocytes located in the mid portion of the left ventricular wall.
• Class of recommendation for the procedure (aortic valve replacement in the case of 
aortic stenosis (AS)): for class I the benefit of the procedure mainly outweighs the risk 
and the procedure should be carried out; for class IIa it is reasonable to carry out the 
procedure; for class IIb the procedure may be considered; and for class III the 
procedure is not recommended because it is not useful and may be harmful.
• Coronary flow reserve: the ratio of maximum blood flow through the coronary arteries 
compared with the normal resting flow. The coronary flow reserve can be measured by 
cardiac catheterization, Doppler echocardiography or positron emission tomography. 
The normal coronary flow reserve ratio is 3-4. In patients with AS, the coronary flow 
reserve is reduced. When the ratio is 1, the coronary flow reserve is exhausted.
• Dobutamine stress echocardiography: echocardiography carried out during 
intravenous infusion of dobutamine, which increases cardiac contractility and flow 
across the aortic valve.
• Mean transvalvular gradient (mean gradient): average value of the pressure loss 
(or gradient) across the aortic valve. This corresponds to the difference between the 
pressure in the left ventricular cavity versus that in the aorta. The mean gradient can 
be measured by Doppler echocardiography or by left heart catheterization.
• Left ventricular afterload: pressure in the wall of the left ventricle during ejection.
• Left ventricular ejection fraction (LVEF): measurement of how much blood is being 
pumped out of the left ventricle of the heart. It is calculated as the percentage 
decrease in the volume of the left ventricular cavity. It can be measured by 
echocardiography, angiography or cardiac magnetic resonance.
• Left ventricular longitudinal function: longitudinal (that is, long-axis direction) 
contraction of the left ventricular wall that is mainly driven by the myocytes located in 
the subendocardial layer of the left ventricular wall.
• Longitudinal strain: percentage shortening of the left ventricular wall in the 
longitudinal axis during systole. The longitudinal strain can be measured by speckle 
tracking echocardiography.
• Peak aortic jet velocity: peak value of the blood flow velocity across the aortic valve. 
The blood velocity is measured by continuous-wave Doppler.
• Radial function: longitudinal (that is, short-axis direction) contraction of the left 
ventricular wall that is mainly driven by the myocytes located in the mid-wall layer of 
the left ventricular wall.
• Stress AVA: AVA measured by Doppler echocardiography during dobutamine or 
exercise stress.
• Stress mean gradient: mean gradient measured by Doppler echocardiography during 
dobutamine or exercise stress.
• Stroke volume index: stroke volume (that is, volume of blood ejected by the heart 
during systole) indexed to (divided by) the patient’s body surface area.
• Transvalvular velocity: blood flow velocity across the aortic valve.
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anatomy and morphology, the haemodynamic severity 
of AS, the response of the left ventricle to the pressure 
overload caused by AS and the patient’s symptomatic 
status3,4. On the basis of these assessments, patients can 
be diagnosed with mild, moderate or severe AS, which 
can all occur in the presence or absence of symptoms 
(TABLE 1). Although Doppler echocardiography is the 
primary modality to assess the stage of AS, cardiac cath-
eterization, which can measure cardiac blood pressure 
and flow, may be used to confirm the haemodynamic 
severity of the stenosis in patients with inconclusive or 
discordant echocardiography results157. However, this 
invasive technique is associated with increased risk of 
bleeding and cerebral embolism158, and should therefore 
only be considered in patients in whom the reclassifi-
cation of the stenosis severity by catheterization would 
change the therapeutic management of the patient (such 
as AVR versus conservative management). For exam-
ple, individuals who might benefit from catheterization 
assessment include symptomatic patients for whom a 
diagnosis of moderate AS versus severe AS cannot be 
decided using echocardiography. 
Patients at risk for AS. Individuals with aortic sclero-
sis and those with a bicuspid valve (irrespective of the 
presence or absence of sclerosis) are considered to be at 
risk of developing AS. The identification of a bicuspid 
valve is usually done by echocardiography but might 
require other imaging modalities such cardiac magnetic 
 resonance (CMR) or CT if the valve is calcified.
Aortic valve sclerosis is defined echocardiographi-
cally by focal areas of valve calcification and thicken-
ing with normal leaflet mobility and normal valvular 
haemo dynamics (FIG. 7; TABLE 2). A systolic outflow mur-
mur may be auscultated on physical examination. 
Although aortic sclerosis is clinically asymptomatic, its 
presence is independently associated with a 40% increase 
in the risk of a coronary event and a 50% increase in 
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Figure 7 | Assessment of AS severity by Doppler echocardiography. For each degree of disease severity, including 
aortic valve sclerosis (part a), mild aortic stenosis (AS) (part b), moderate AS (part c) and severe AS (part d), this figure 
shows a 2D echocardiographic short-axis view of the aortic valve (top left panel, indicated with arrows), the transvalvular 
velocity by continuous-wave Doppler (right panel) and the multidetector CT (MDCT) view of aortic valve calcification 
(bottom left panel). In the patient with aortic sclerosis (part a), there are some small isolated spots of calcification (appears 
white on the MDCT images, circled) in the aortic valve leaflets but there is no obstruction to blood flow (that is, no 
stenosis). The peak aortic jet velocity (1.47 m per s), mean gradient (5 mm Hg) and aortic valve area (AVA; 2.87 cm2) are 
normal. In the patient with mild AS (part b), there is mild aortic valve calcification with mild obstruction to blood flow. 
The peak aortic jet velocity is 2.08 m per s, the mean gradient is 9 mm Hg and the AVA is 1.62 cm2. In the patient with 
moderate AS (part c), there is more extensive aortic valve calcification with moderate obstruction of blood flow: the peak 
aortic jet velocity is 3.51 m per s, the mean gradient is 28 mm Hg and the AVA is 1.21 cm2. In the patient with severe AS 
(part d), there is severe aortic valve calcification and severe obstruction to blood flow: the peak aortic jet velocity is 4.35 m 
per s, the mean gradient is 48 mm Hg and the AVA is 0.75 cm2.
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the risk of cardiovascular death159. The mechanism of 
adverse outcomes with aortic sclerosis is not entirely 
clear but the presence of aortic valve mineralization 
might be a marker for atherosclerosis and/or for altered 
 phospho-calcium metabolism22,160.
Mild or moderate AS. Patients with mild or moderate AS 
(FIG. 7; TABLES 1,2) are generally asymptomatic unless they 
have other comorbidities that contribute to the emergence 
of symptoms. Classic physical findings of AS are a harsh, 
crescendo–decrescendo systolic murmur, a single sec-
ond heart sound and a delayed carotid upstroke (BOX 1). 
Using Doppler echocardiography, the haemodynamic 
severity of AS can be measured accurately and reliably 
on the basis of the peak aortic jet velocity, mean trans-
valvular pressure gradient (mean gradient) and aortic 
valve area (AVA). With the development of calcific AS, 
there is a progressive reduction in the AVA that causes an 
acceleration of the flow (that is, increase in peak aortic jet 
velocity) and a loss of pressure (that is, increase in mean 
gradient) across the valve (FIG. 6; TABLE 2). AS is suspected 
upon the visualization of a thickened aortic valve with a 
restricted opening, and confirmed by the presence of an 
increased peak aortic velocity or mean pressure gradient. 
Echocardiography is also useful to assess the effects of AS 
on the geometry and the function of cardiac chambers, 
particularly of the left ventricle (FIGS 5,6).
Severe AS. Patients with severe AS (typically, those who 
have a peak aortic jet velocity of ≥4 m per s, a mean gra-
dient of ≥40 mm Hg and an AVA of ≤1 cm2; TABLES 1,2) 
may or may not have symptoms, and require a closer 
clinical and Doppler echocardiographic follow-up than 
those with mild or moderate forms of the disaese3. 
Classic symptoms of severe AS include dyspnoea and 
other symptoms of heart failure, angina and syncope. 
Patients with severe AS who are apparently asympto-
matic according to medical history and physical exami-
nation should undergo exercise testing to confirm their 
asymptomatic status. Indeed, about one-third of patients 
with severe AS who are a priori asymptomatic in fact 
have exercise-limiting symptoms detected at an exercise 
stress test, and these patients should be referred for 
AVR161,162. In addition, a potential marker for risk in AS 
is a marked increase in mean gradient (absolute increase 
in gradient >18–20 mm Hg) during exercise stress echo-
cardiography, which predicts higher risk of cardiac 
events in the short term, independent of symptoms161,162.
Low-gradient AS. The majority of patients with severe AS 
have a high peak aortic jet velocity and gradient (mean 
gradient ≥40 mm Hg). However, a substantial propor-
tion of patients may have a low peak aortic jet velocity 
and mean gradient despite the presence of a small AVA 
(<1.0 cm2). The most frequent cause of ‘low-gradient’ 
AS is the presence of a low-flow state. There are two 
main subtypes of low-flow, low-gradient AS (TABLES 1,2): 
‘classical’ low-flow (stroke volume index <35 ml per 
m2), low-gradient (mean gradient <40 mm Hg) AS with 
reduced LVEF (<50%)163; and ‘paradoxical’ low-flow 
(stroke volume index <35 ml per m2), low-gradient (mean 
gradient <40 mm Hg) AS with preserved LVEF (≥50%)164.
In classical low-flow, low-gradient AS, the decrease 
in stroke volume, and thus in transvalvular flow rate 
(stroke volume divided by left ventricular ejection time), 
are predominantly related to left ventricular systolic dys-
function, whereas in paradoxical low-flow, low-gradient 
AS, the low-flow state is generally due to pronounced left 
ventricular concentric remodelling with impaired left 
ventricular diastolic filling and reduced left ventricular 
longitudinal systolic function156. Other conditions, such 
as mitral regurgitation, mitral stenosis or atrial fibril-
lation can also contribute to the reduced left ventricu-
lar outflow in both classical and paradoxical low-flow, 
low-gradient AS.
In the presence of low flow, it is therefore difficult 
— using resting Doppler echocardiography or catheteri-
zation — to differentiate truly severe stenosis from pseu-
do-severe stenosis; that is, a situation in which the stroke 
volume is not sufficient to completely open a valve that 
is only mildly or moderately stenotic. In such low-flow 
conditions, the gradient might underestimate the steno-
sis severity, whereas the AVA might overestimate the 
severity. Low-dose dobutamine stress echocardiography 
Table 2 | Parameters and criteria for the assessment of aortic stenosis severity
Technique Parameter Aortic 
sclerosis






VPeak <2 m per s 2–3 m per s 3–4 m per s ≥4 m per s ≥5 m per s <4 m per s
ΔPMean <10 mm Hg 10–19 mm Hg 20–39 mm Hg ≥40 mm Hg ≥50 mm Hg <40 mm Hg
AVA = SVLVOT/VTIAo >2.0 cm
2 1.6–2.0 cm2 1.1–1.5 cm2 ≤1.0 cm2 ≤0.6 cm2 ≤1.0 cm2




0.7–0.9 cm2 per m2 ≤0.6 cm2 per m2 ≤0.45 cm2 
per m2






NA NA NA NA NA ≥40 mm Hg
Stress AVA NA NA NA NA NA ≤1.0 cm2
MDCT Aortic valve 
calcification score
NA NA • Men ≥1,200 AU
• Women ≥700 AU
• Men ≥2,000 AU
• Women ≥1,200 AU
NA • Men ≥2,000 AU
• Women ≥1,200 
AU
ΔPMean, mean transvalvular gradient; AVA, aortic valve area; AVAi, indexed AVA; BSA, body surface area; MDCT, multidetector CT; NA, not applicable or not available; 
SVLVOT, stroke volume measured at the left ventricular outflow tract; VPeak, peak aortic jet velocity; VTIAo, velocity–time integral of the transvalvular flow.
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should be used for patients with classical (low LVEF) 
low-flow, low-gradient AS to confirm stenosis severity. 
Dobutamine is used to mimic the effect of exercise on 
the heart, thereby increasing cardiac blood flow. Patients 
with a mean gradient of ≥40 mm Hg (or a peak aortic 
jet velocity of ≥4 m per s) and an AVA of <1.0 cm2 with 
dobutamine stress echocardiography are considered to 
have truly severe AS (TABLE 2). In patients who show per-
sistent discordant grading (small AVA with a low mean 
gradient) during dobutamine stress echocardiography, 
it is useful to calculate the projected AVA at normal 
flow rate; a projected AVA of <1.0 cm2 suggests that the 
patient has truly severe stenosis165,166. Patients who have 
no or minimal increase in stroke volume (increase of 
<20%) upon dobutamine administration have a high risk 
of operative mortality with surgical AVR163,167. Low-dose 
dobutamine stress echocardiography or dobutamine 
stress cardiac catheterization may also be used in 
patients with paradoxical low-flow, low-gradient AS168. 
However, these approaches are often not feasible owing 
to the presence of restrictive left ventricular physiology 
or because their results are inconclusive owing to limited 
increases in flow in response to stress.
In patients with classical or paradoxical low-flow, 
low-gradient AS in whom dobutamine stress echo-
cardiography is not feasible or inconclusive, multi-
detector CT (MDCT), which is a high-resolution form 
of CT, can be used to quantify aortic valve calcium load 
and thereby corroborate stenosis severity and indication 
of AVR (FIG. 7; TABLE 2). The region of the aortic valve is 
assessed in contiguous axial slices and the calcium score 
is measured by the Agatston-modified method, in which 
calcification is defined as 4 adjacent pixels with density 
>130 Hounsfield units on the MDCT images. Studies 
have shown that different cut-off values of aortic valve 
calcium score (AU) should be used in women (>1,200 
AU) compared with men (>2,000 AU) to identify hae-
modynamically severe stenosis169,170. Furthermore, 
these studies suggest that aortic valve calcium density 
(the ratio of calcium load to cross-sectional area of the 
aortic annulus) might be superior to absolute calcium 
load in predicting haemodynamic severity and clini-
cal outcomes. These studies also showed that different 
cut-off values should be used in women (>300 AU per 
cm2) compared with men (>500 AU per cm2)169,170. The 
aortic valve calcium load or density is also a powerful 
predictor of the risk of fast stenosis progression and 
of mortality170–172.
Finally, a substantial proportion of patients with AS 
have a small AVA and low mean gradient but a normal 
flow (stroke volume index >35 ml per m2). This cate-
gory is often referred to as normal-flow, low-gradient 
AS and might be related to inherent discrepancies in the 
criteria used to define severe AS (in terms of AVA and 
mean gradient)173 and/or to markedly reduced aortic 
compliance169. Patients with normal-flow, low-gradient 
AS generally have less advanced disease and better out-
comes compared with patients who have high-gradient 
or low-flow, low-gradient AS174. However, if the patient is 
symptomatic, aortic valve calcium scoring using MDCT 
can be considered to confirm stenosis severity169.
Emerging biomarkers
Other imaging or blood biomarkers of the severity of AS, 
and its deleterious effects on the left ventricle and other 
cardiac chambers, may also be useful to predict risk of 
rapid disease progression and adverse events. These bio-
markers may be particularly helpful in identifying patients 
with asymptomatic severe AS who may benefit from early 
‘prophylactic’ AVR.
Biomarkers of aortic valve biology and flow pattern. 
Positron emission tomography (PET) combined with 
MDCT (PET-MDCT) is a feasible and reproducible 
method that combines anatomical imaging from MDCT 
with molecular imaging from PET. The valvular uptake of 
18F-sodium fluoride (18F-NaF) measured by PET-MDCT 
is a marker of an active mineralization process within the 
valve175–177 (FIG. 8). 18F-NaF uptake correlates well with AS 
severity and it might provide incremental value beyond 
aortic valve calcium scoring to predict AS progression 
over time172. This method might also be useful in assessing 
the effect of new pharmacotherapies on AS progression. 
In addition, CMR might be useful to assess valve biology 
and flow. For instance, data from a previous study suggest 
that in the future CMR might be able to assess not only the 
amount of valvular calcification (as can be achieved with 
MDCT) but also the amount of fibrous-rich and lipid-rich 
valve tissue178. Moreover, CMR with four-dimensional 
flow modality might also one day be used to visualize 
flow patterns in the aorta and therefore to identify patients 
with AS who are at risk of developing aortic aneurysm and 
aortic dissection (a breach in the lining of the aorta that 
causes blood to flow between the layers of the wall of the 
aorta, forcing layers apart)179,180 (FIG. 9).
Biomarkers of the effect of AS on the left ventricle. 
Detection of subclinical left ventricular dysfunction using 
biomarkers might prove useful in identifying patients who 
may need early therapeutic intervention. For example, 
reduced longitudinal strain is useful to identify subclinical 
left ventricular dysfunction and to predict risk of cardiac 
events in patients with asymptomatic AS and preserved 
LVEF181–186. However, further studies are needed to har-
monize the different strain analysis platforms between 
vendors and to propose an optimal cut-off value of lon-
gitudinal strain that identifies patients at high risk of 
develop ing left ventricular dysfunction and symptoms in 
the short term.
Blood levels of B-type natriuretic peptide (BNP) might 
also be a useful marker of left ventricular function, as it is 
secreted from the left ventricle in response to mechanical 
stress. Although BNP can be used for risk stratification, 
there is an important inter-study variability in the cut-off 
serum values of BNP that have been used to identify high-
risk patients. A 2014 study proposed the use of the BNP 
ratio (the measured value of BNP divided by the expected 
value of BNP, adjusted for the age and sex of the patient) 
to overcome this limitation. A BNP ratio of >1 was found 
to be a powerful independent predictor of mortality in 
AS, even in patients with asymptomatic AS187. Hence, the 
BNP ratio as well as its increase during follow-up might 
be helpful in enhancing risk stratification in AS.
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Besides longitudinal strain and BNP, the extent of 
myocardial fibrosis represents a maladaptive response of 
the left ventricle to pressure overload from AS. Previous 
studies188–191 have reported that approximately 20–30% 
of patients undergoing AVR for severe AS have severe 
myocardial fibrosis documented by CMR or myocardial 
biopsies. Myocardial fibrosis is often not reversible (or 
only partially reversible) and is associated with increased 
risk of cardiovascular events and mortality during fol-
low-up as well as persistence of left ventricular dysfunc-
tion and symptoms following AVR188–190,192,193. Therefore, 
the quantification of myocardial fibrosis by CMR (FIG. 10) 
could potentially be useful in recommending early AVR 
in patients with asymptomatic severe AS before extensive 
fibrosis and ensuing irreversible myocardial dysfunction 
have developed or to improve operative risk stratifica-
tion and to assess potential utility versus futility of AVR 
in patients with low-flow, low-gradient AS. However, 
further studies are needed to improve the standardiza-
tion of the different CMR methods for quantification of 
myocardial fibrosis and to establish the thresholds that 
should be used clinically to identify patients who are at 
risk for irreversible myocardial dysfunction. The large-
scale use of CMR in the AS population is also limited by 
its high cost and low availability.
Emerging blood biomarkers, such as high- sensitivity 
cardiac troponin194,195, growth/differentiation factor 15 
(GDF15), soluble IL-1 receptor-like 1 (IL-1RL1; also 
known as ST2) and miRNAs196–198, might be helpful to 
detect subclinical and/or irreversible myocardial dys-
function, but their incremental value beyond established 
clinical, echocardiographic, tomographic and blood 
 biomarkers remains to be shown.
The main limitation of all aforementioned imaging 
and blood biomarkers of left ventricular function is 
that they are non-specific and may be altered by other 
concomitant diseases, such as hypertension, diabetes 
mellitus and coronary artery disease. Therefore, these 
biomarkers should always be interpreted in conjunc-
tion with the standard parameters of stenosis sever-
ity. Finally, further studies are needed to establish the 
incremental role of these emerging blood or imaging 
biomarkers to identify the patients who might benefit 
from earlier intervention.
Conclusions
In summary, the two main risk factors for calcific AS are 
older age and bicuspid aortic valve. Other risk factors 
include metabolic syndrome, diabetes, hypertension, 
smoking and increased plasma Lp(a). There is currently 
no preventive or pharmaco-therapeutic approach that 
has proved effective to prevent the onset or to slow the 
progression of calcific AS. The initial screening for this 
disease is generally based on the auscultation of a sys-
tolic murmur by the primary care physician or general 
cardiologist. Doppler echocardiography is the method of 
choice to diagnose AS and to assess its severity as well as 
to follow disease progression over time. Quantification 
of aortic valve calcium load by MDCT may be useful to 
corroborate stenosis severity in patients in whom echo-
cardiography is neither feasible nor conclusive, which is 
often the case in the setting of low-flow, low-gradient AS. 
Measurement of circulating BNP levels, assessment of 
global longitudinal strain by speckle tracking and detec-
tion of myocardial fibrosis by CMR are emerging bio-
markers that might improve the detection of subclinical 
left ventricular dysfunction and thus the determination 
of the optimal timing for AVR.
Management
The only treatment available to patients with sympto-
matic severe AS is to implant a prosthetic heart valve 
either surgically or percutaneously (through a catheter). 
The therapeutic management is similar for calcific and 
rheumatic AS. As discussed above, there is no pharma-
cotherapy that specifically targets AS to prevent pro-
gressive leaflet calcification or to delay the time to valve 
replacement3,199. Although there was hope that statins 
would fill that void, several randomized trials showed 
no effect of statins on haemodynamic progression or 
AS-related clinical events152–154. However, the combi-
nation of simvastatin (a drug that lowers plasma LDL 
cholesterol levels) and ezetimibe (a drug that decreases 
cholesterol absorption in the small intestine) did reduce 
ischaemic cardiovascular events in patients with mild 
to moderate AS153. Therefore, as valve stenosis pro-
gresses into the moderate to severe range, greater vigi-
lance is required in terms of assessment for symptoms 
associated with significant AS, to decide when to carry 
out AVR.
Management decisions regarding AVR are often 
straightforward (FIG. 11). However, in the current era 
of transcatheter AVR (TAVR), there are more options 
to consider when intervention is contemplated than 
Figure 8 | Assessment of aortic valve mineralization activity by PET-CT. Coaxial short 
axis views of the aortic valve from one patient with aortic sclerosis, one patient with mild 
aortic stenosis (AS) and one patient with moderate AS. a | Left panels show baseline 
multi-detector CT (MDCT) images of the aortic valve; regions of macrocalcification 
appear white. b | Middle panels show baseline fused MDCT and 18F-sodium fluoride 
(18F-NaF) positron emission tomography (PET) images showing intense 18F-NaF uptake 
(red and yellow areas) both overlying and adjacent to existing calcium deposits on the 
MDCT. c | Right panels show 1-year follow-up (without intervention) MDCT images 
indicating increased calcium accumulation in much the same distribution as the baseline 
PET activity. Figure is reproduced with permission from REF. 172, Elsevier.
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in previous decades (FIGS 12,13). In addition, older 
(>80 years of age) and sicker patients who were not 
previously candidates for definitive therapy are being 
treated200,201. Increasingly, clinicians must integrate com-
plex information about the severity of AS, ambiguous 
symptoms, left ventricular remodelling and function, 
comorbidities, frailty and disabilities to make decisions 
on whether, when and how to carry out AVR3,199,202. This 
complex information ought to be discussed and debated 
by a heart valve team — a multidisciplinary group of 
cardiac surgeons, interventionalists, cardiac imaging 
experts, and often nurses, geriatricians and anesthesiol-
ogists203–205. In addition, it is important for management 
decisions to centre on patients and not to be myopically 
focused on AS severity alone3. First, it should be decided 
whether valve replacement is indicated. Next, consider-
ation can be given to how the valve should be replaced 
(surgical versus transcatheter) (FIGS 12,13; TABLE 3). 
Finally, at any stage of AS, associated medical condi-
tions such as atrial fibrillation, coronary disease, hyper-
tension and heart failure should be treated  according to 
 guideline recommendations3,4,199.
Indications for aortic valve replacement
Symptomatic severe AS. Severe high-gradient AS 
accompanied by symptoms related to AS is the most 
common and straightforward indication for AVR, 
and those with severe AS who present with symptoms 
and/ or left ventricular systolic dysfunction (defined as 
a LVEF of <50%) have a firm (class I; BOX 1) indication 
for AVR3,4 (FIG. 11; TABLE 1). Low-flow, low-gradient AS 
presents somewhat of a challenge, as the combination 
of a small AVA with a low gradient raises uncertainty 
about the severity of the stenosis and thus the indication 
of AVR. Symptomatic patients with classical low-flow, 
low-gradient and reduced LVEF (<50%) are reasonable 
candidates for AVR (class IIa indication; BOX 1) pro-
vided that there is anatomic evidence (MDCT calcium 
score) or haemodynamic evidence (peak aortic jet 
velocity of ≥4 m per s or mean gradient of ≥40 mm Hg 
with dobutamine stress echocardiography) that the AS 
is truly severe3,4,170. AVR may be considered in patients 
with classical low-flow, low-gradient AS who have no 
flow reserve with dobutamine stress echocardiogra-
phy, but the operative risk is higher4,163,167,206. It is also 
reasonable to carry out AVR in symptomatic patients 
with paradoxical low-flow, low-gradient and preserved 
LVEF (≥50%; class IIa indication) provided there is 
clinical, haemodynamic and anatomical evidence that 
the obstruction is severe and is the most likely cause of 
symptoms3,4,168. Although there has been some debate 
about the outcome and the therapeutic management of 
patients with paradoxical low-flow, low-gradient AS, a 
recent meta-analysis confirms that these patients have 
worse outcomes than those with moderate or high- 
gradient severe AS, and that their survival is markedly 
improved by AVR174.
Asymptomatic severe AS. Patients with severe AS who 
are asymptomatic by history but who have a reduced 
LVEF (<50%; TABLE 1), or who are undergoing another 
cardiac surgical procedure, should have their valve 
replaced (class I indication)3,4 (FIG. 11). It is also reason-
able to carry out AVR (class IIa indication) in asymp-
tomatic patients with severe AS and decreased exercise 
tolerance, or who show a drop in blood pressure with 
exercise, and in those at low surgical risk with very 
severe AS (peak aortic jet velocity >5 m per s or 5.5 m 
per s, depending on the guidelines), or in those who 
have findings suggestive of rapid progression (severe 
valve calcification or increase in peak aortic jet velocity 
of ≥0.3 m per s per year)3,4.
Figure 9 | Assessment of flow patterns in the aorta by 4D flow cardiac magnetic resonance according to aortic 
valve phenotype. a | A normal valve systolic flow in a healthy control. b | A tricuspid aortic valve (TAV) with severe aortic 
stenosis (AS) and altered systolic flow with helical patterns in the ascending aorta. c | A bicuspid aortic valve (BAV) with 
right–left cusp fusion and severe AS. Altered blood flow with asymmetrical helical flow patterns are observed in the 
proximity of the aortic valve. Vpeak, peak aortic jet velocity. Image courtesy of J. Garcia, A. Barker and M. Markl, 
Northwestern University, Chicago, Illinois, USA.
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Surgical aortic valve replacement
The first successful surgical AVR was carried out in 
1960 (REF. 207). Over the past half century, tremendous 
advances in operative management, techniques and 
valve design have transformed the outlook for patients 
with AS. Despite increasing age and comorbidities, the 
mortality associated with AVR has decreased dramat-
ically during the past two decades208,209. For an isolated 
AVR, the overall 30-day mortality rate is currently 
<3% as reported in the Society of Thoracic Surgeons 
(STS) database and German Aortic Valve Registry 
(GARY)209,210. TABLE 3 presents the advantages and limit-
ations of the different types of AVR. There has been 
a shift away from mechanical valves towards greater 
use of bioprosthetic valves, particularly in patients 
>65  years of age209 (FIG.  12). Increasingly, younger 
patients or those with an active lifestyle opt for a bio-
prosthetic valve to avoid anticoagulation, despite its 
shorter durability compared with a mechanical valve. 
The most frequently used bioprosthetic valves are the 
stented bioprostheses, which are composed of three bio-
logical leaflets made from porcine aortic valve or bovine 
pericardium and mounted on a metal or polymeric 
stented ring. Bioprosthetic valves also include stentless 
bioprostheses that are manufactured from intact por-
cine aortic valves or from bovine pericardium. These 
valves have better haemodynamics compared with 
stented valves but their implantation is more complex 
and thus requires longer cardiopulmonary bypass time. 
Sutureless stent-mounted bioprosthetic valves have also 
been developed to allow easier and faster implantation 
of the valve without sutures. Additional alternatives for 
AVR in younger patients include the implantation of an 
aortic homograft (aortic valve collected from a donor) 
or the Ross procedure, which involves the replacement 
of the diseased aortic valve with the patient’s pulmonary 
valve followed by pulmonary valve replacement using 
a donor pulmonary valve211–213. However, these options 
are more controversial and less frequently used. A recent 
propensity analysis showed no difference in mortality or 
stroke among patients 50–69 years of age treated with a 
bioprosthetic valve versus a mechanical valve, although 
a bioprosthetic valve was associated with a higher inci-
dence of reoperation and a mechanical valve was asso-
ciated with a higher incidence of major bleeding during 
the 15-year follow-up214. A mini sternotomy, which is a 
minimally invasive way of carry ing out cardiac surgery, 
is a viable option for isolated AVR and is associated with 
similar mortality, but decreased morbidity and resource 
use, compared with a full sternotomy215.
Operative mortality for AVR varies according to the 
skill and the experience of the surgical team as well as 
hospital volume216. Increasing age and comorbidities 
substantially increase both operative and long-term 
mortality after AVR217,218. Several risk scores, including 
the EuroSCORE (http://www.euroscore.org) and the 
STS risk calculator (http://riskcalc.sts.org), incorporate 
these factors to estimate operative risk. These risk scores 
are imperfect and being refined iteratively. They often 
do not include important factors such as frailty, chest 
wall radiation, porcelain aorta, pulmonary hyperten-
sion and liver cirrhosis. Owing to age, left ventricular 
dysfunction, multiple comorbidities and other factors, 
approximately one-third of patients with indications for 
AVR are not treated200,219.
Transcatheter aortic valve replacement
TAVR is a minimally invasive procedure that involves 
insertion of a bioprosthetic aortic valve within the ori-
fice of the native stenotic valve using a catheter (FIG. 13). 
For patients at high or prohibitive risk of operative 
mortality with surgical AVR, TAVR has been a trans-
formative innovation, providing a life-saving treatment 
for patients who were previously not candidates for 
AVR201,220–224 (TABLE 3). In the PARTNER Trial, there was a 
20% absolute reduction in 1-year mortality (hazard ratio, 
0.55; 95% confidence interval, 0.40 to 0.74) with TAVR 
compared with standard therapy (30.7% versus 50.7%, 
respectively)201. This survival benefit was accompanied 
by relief of symptoms and improvement in functional 
capacity in many patients201,225. Randomized trials of 
balloon-expandable and self-expanding valves have also 
showed that TAVR is a viable alternative to surgery in 
patients at high risk for AVR220,221 (TABLE 4).
TAVR may be carried out by several different 
approaches: the most common access routes include 
transfemoral, transapical and transaortic routes 
(FIG. 13; TABLE 5). Approximately two-thirds (56–75%) 
of TAVR procedures are carried out via a transfemo-
ral approach226–229. As catheter sheath sizes decrease, 
the balance is anticipated to shift even further towards 
a transfemoral approach. A transfemoral approach is 



















Figure 10 | Assessment of myocardial fibrosis by cardiac magn tic resonance in 
patients with AS. Top panel shows colour maps of T1 values using shortened modified 
Look–Locker inversion in a mid-ventricular short-axis slice and bottom panel shows the 
corresponding slice with late gadolinium enhancement (LGE) imaging. The left panel 
shows a normal volunteer, the middle panels show moderate aortic stenosis (AS) with 
moderate left ventricular hypertrophy and the right panel shows severe AS with severe 
left ventricular hypertrophy. Regions with high T1 values (orange and red) within the left 
ventricular wall correspond to myocardial fibrosis. Reproduced from Human 
non‑contrast T1 values and correlation with histology in diffuse fibrosis, Bull, S. et al. 99, 
932–937 (2013) with permission from BMJ Publishing Group Ltd.
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associated with lower mortality and quicker recov-
ery than alternative access approaches227–229. Other 
approaches include access via the subclavian, axillary or 
carotid arteries. There have also been recent reports of 
transcaval approaches230.
Balloon-expandable and self-expanding tran-
scatheter valves have so far been the most rigor-
ously studied valve types, specifically the CoreValve 
(Medtronic, Dublin, Ireland) and SAPIEN (Edwards, 
Irvine California, USA) valves201,220,221,224,226,231,232 (FIG. 13; 
TABLE 5). This clinical arena is a very active area of 
development that includes iterative improvements on 
existing valves and novel designs233. Although TAVR has 
been a successful therapy in many ways, several com-
plications and challenges have been encountered233. 
The most notable has been paravalvular aortic regurgi-
tation234–236. The association between moderate or severe 
paravalvular aortic regurgitation and increased mortal-
ity has been clearly established, with some studies even 
suggesting that this adverse association extends to mild 
regurgitation235,237,238. Other complications of TAVR 
have included major vascular injury, heart block requir-
ing a permanent pacemaker and acute kidney injury; 
more rare complications include stroke, aortic rupture 
and coronary obstruction233.
The TAVR field is evolving rapidly. Clinical trials 
comparing TAVR with surgery in intermediate risk 
populations are ongoing with results expected soon 
(TABLE 4). Surgical AVR has excellent results with low 
mortality in low risk populations209. For TAVR to make 
inroads into lower risk populations, device improve-
ments are needed (principally to reduce paravalvular 
regurgitation and heart block, which is an arrhythmia 
that occurs when electrical impulses in the heart are 
blocked or delayed), vascular and stroke complications 
must be minimized and valve durability needs to be 
shown. There is a growing movement away from general 
anaesthesia to conscious sedation that might decrease 
the morbidity associated with the procedure239. Finally, 
valve-in-valve procedures for failed bioprostheses are 
becoming more common as an alternative to re-doing 
surgical AVR240.
Surgical or transcatheter aortic valve replacement
The choice of how to carry out AVR should occur 
only after a decision that AVR is indicated3 (TABLE 1). 
Surgical AVR is currently indicated for patients with 
low to moderate surgical risk and TAVR is indicated for 
patients at prohibitive risk for surgery3,4 (FIG. 11; TABLE 3). 
Patients may be at prohibitive risk for surgery owing to 
Figure 11 | Algorithm for the management of AS. This figure presents the algorithm recommended by the 2014 
American College of Cardiology/American Heart Association guidelines for the management of aortic stenosis (AS)3.  
AVA, aortic valve area; AVAi, AVA indexed for body surface area; AVR, aortic valve replacement; BP, blood pressure;  
DSE, dobutamine stress echocardiography; ETT, exercise treadmill test; LVEF, left ventricular ejection fraction; SVI, stroke 
volume index; TAVR, transcatheter aortic valve replacement; VPeak, peak aortic jet velocity.
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DSE with Vpeak ≥4 m/s
or mean gradient
≥40 mm Hg and AVA
≤1.0 cm2 at any ﬂow rate
Vpeak <4 m/s Vpeak ≥5 m/s and low surgical riskVpeak ≥4 m/s
Symptoms due to AS No AS symptoms
Abnormal aortic valve with reduced systolic opening
Class I Class IIa Class IIb
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technical factors (such as porcelain aorta) or for clinical 
reasons (such as multiple comorbidities or frailty)3,241. 
Intermediate-risk patients may be treated with surgical 
AVR or enrolled in a clinical trial for TAVR. High-risk 
patients who are candidates for either surgical AVR or 
TAVR should have their therapy determined by care-
ful consideration by the heart valve team3,4. Factors of 
importance to this decision include anatomical consid-
erations, concomitant coronary disease and associated 
mitral or tricuspid valve disease. In patients with con-
siderable associated mitral or tricuspid regurgitation, 
it is unclear whether concomitant surgical repair of 
the mitral or tricuspid valve at the time of AVR would 
improve clinical outcomes242,243.
Although TAVR is generally associated with a sur-
vival advantage compared with conservative (no AVR) 
management, there is a sizeable subgroup that dies soon 
after TAVR or does not experience an improvement in 
quality of life, suggesting potential futility of TAVR 
in some patients201,202,220,244,245. For instance, among inop-
erable patients treated with TAVR in the PARTNER I 
Cohort B trial (TABLE 4), at 1 year after the procedure, 
approximately 31% had died and 18% had less than a 
moderate improvement in their quality of life or New 
York Heart Association functional class201,244. Among 
patients treated in the high-risk Cohort A of the 
PARTNER I trial with TAVR or surgical AVR (TABLE 4), 
death from non-cardiovascular causes was more com-
mon than death from cardiovascular causes48. Moreover, 
when cause of death was difficult to categorize, it often 
occurred in frail patients who were failing to thrive246. 
Therefore, when lifespan or quality of life is markedly 
limited by frailty, non-cardiac disease, or mental or phys-
ical disability, the potential benefit of AVR may be low11. 
These cases highlight the importance of a heart valve 
team in the management decisions of these complex 
patients3,4. In some of these patients, the most appro-
priate approach is palliative care, taking the values and 
preferences of the patient and family into consideration 
in the decision-making process202.
Management of coronary disease in patients with AS
The prevalence of coronary disease in the setting of 
severe AS increases with age and was as high as 75% in 
recent trials involving mostly very elderly patients201,220. 
Decisions regarding revascularization at the time of valve 
replacement used to be somewhat simpler when surgical 
valve replacement was the only option. If considerable 
coronary artery stenosis was present at preoperative cor-
onary angiogram, coronary artery bypass graft was car-
ried out at the time of valve replacement surgery. With 
the emergence of TAVR, decisions regarding the treat-
ment of coronary disease have become more complex, 
including which coronary lesions to treat versus which 
to leave alone, how to treat them (percutaneous versus 
bypass) and when to treat them (before, during or after 
valve replacement)247. These decisions are influenced by 
numerous factors including lesion location and com-
plexity, overall burden of coronary disease, the presence 
or absence of angina, left ventricular function, bleed-
ing risk on dual antiplatelet therapy and other factors. 
How these decisions affect clinical outcomes requires 
further investigation, as many questions remain247,248. 
The way in which coronary disease should influence 
decisions between valve replacement with TAVR and 
surgical valve replacement is also unclear in some sce-
narios. A detailed discussion of these complex decisions 
is beyond the scope of this Primer, but has been recently 
reviewed elsewhere247,249.
Balloon aortic valvuloplasty
Balloon aortic valvuloplasty (BAV), which uses the 
pressure of an inflated balloon to widen the opening 
of the stenotic valve, is not a definitive therapy for AS3. 
The changes produced by BAV in the valve area and 
transvalvular pressure gradient are usually modest and 
short-lived (weeks to months)250,251. In particularly ill 
patients, BAV may be used as a ‘bridge’ to stabilize the 
patient prior to definitive therapy with valve replace-
ment3. When there is uncertainty as to whether a patient 
will benefit clinically from valve replacement owing to 
Figure 12 | Different types of surgical aortic valve replacement. a | Surgical aortic valve replacement with a bileaflet 
mechanical valve. b | Surgical aortic valve replacement with a bioprosthetic valve.
b
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markedly depressed left ventricular function or con-
comitant oxygen-dependent lung disease, or other 
factors, a BAV may have diagnostic use to determine 
whether valve replacement is appropriate202. In patients 
with severe AS who are undergoing non-cardiac sur-
gery, a BAV is generally not warranted unless the patient 
is symptomatic or haemodynamically unstable and 
needs to undergo non-cardiac surgery before aortic 
valve replacement can be carried out3. In some circum-
stances, a BAV may be used for palliative care as there is 
some evidence that it might provide a short-term benefit 
in terms of improved survival, functional capacity and 
quality of life, but these benefits are not sustained251.
Quality of life
Severe AS primarily impairs quality of life by causing 
heart failure symptoms, including shortness of breath, 
fatigue and diminished functional capacity 199,252. 
However, because patients who develop severe AS are 
usually older adults, these symptoms may also partly 
result from normal ageing, numerous comorbidities or 
frailty202. In older patients at high or extreme surgical 
risk undergoing TAVR, disease-specific and generic 
health status are often extremely poor 221,224,244,245. 
Given the high prevalence of frailty and disability 
in this patient population, the relationship between 
valvular stenosis and overall quality of life is also 
 complex and variable202.
AVR is indicated in patients with severe sympto-
matic AS both to increase life expectancy and improve 
symptoms and quality of life3,4,199,202,252,253. For a patient 
with severe AS and heart failure symptoms, who is at 
low surgical risk, surgical AVR is associated with a 
fairly predictable improvement in shortness of breath 
and functional capacity. For patients who are at high 
risk for surgical interventions, who were previously 
not treated with AVR, TAVR has been a transforma-
tive innovation that has improved survival and quality 
of life200,201. Compared with inoperable patients treated 
with conservative management, patients treated with 
TAVR had less severe heart failure symptoms and better 
disease-specific and generic health status over the year 
after randomization201,244.
To determine the anticipated benefit of valve 
replacement in terms of quality of life, it is important 
to consider how much of the patient’s symptoms and 
impaired health status are due to the valvular obstruc-
tion and heart failure versus other comorbidities and 
geriatric conditions253. This can be challenging to 
determine. When a patient’s diminished quality of 
life is clearly related to heart failure symptoms from 
severe AS, valve replacement conveys a predictable and 
a
b
Nature Reviews | Disease PrimersFigure 13 | Different types of transcatheter aortic valve replacement. a | Transcatheter ao tic valve replac m nt with  
a balloon-expandable valve via the transfemoral, transapical or transaortic approach. b | Transcatheter aortic valve 
replacement with a self-expanding valve via the transfemoral approach.
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noticeable improvement in quality of life and extends 
life expectancy. However, some patients have residual 
heart failure symptoms (albeit not as severe) after valve 
replacement owing to persistent diastolic dysfunction; 
this may manifest in a similar manner to the common 
syndrome of heart failure with preserved LVEF. When 
poor health status is principally due to comorbidities 
and geriatric conditions, valve replacement might lead 
to an unsatisfactory result both in terms of decreased 
survival and a decline or lack of improvement in qual-
ity of life253–256. Elucidating which factors contribute to 
worse quality of life after TAVR and identifying how 
those factors might be targeted with adjunctive inter-
ventions to improve outcomes require further study. 




Although long considered to be a passive and degener-
ative process, it is now clear that calcific AS results from 
an active biology that promotes fibrosis and calcification 
of the valve leaflets1. The pathobiology of AS is complex 
and probably involves genetic factors, multiple signalling 
pathways, ageing, sex hormones, haemodynamic factors 
and shear stress, and the systemic milieu. Disease initia-
tion and progression are influenced by different factors. 
Several laboratories worldwide are working to elucidate 
the pathobiology of aortic sclerosis and stenosis, which 
will probably yield novel insights into potential thera-
peutic targets to prevent or to reverse calcific aortic 
valve disease.
Pilot trials to slow disease progression
Several intervention studies have been carried out to 
test the hypothesis that lipid lowering with statin medi-
cations would slow the progression of AS; however, the 
results were generally disappointing152–154. With new 
insights into valve biology, there will probably be a new 
wave of clinical trials testing interventions that target 
diverse pathways to slow the progression of (or even 
reverse) calcific AS. Specific interventions might target 
the initiation of disease or the progression of disease. 
Promising targets on the horizon include Lp(a), the 
renin–angiotensin system, RANKL and ectonucleoti-
dases. Novel composite end points are likely to be devel-
oped for these trials based on the mechanism of action 
of the intervention and the phase of disease targeted.
AS as a disease of the left ventricle
The left ventricular response to chronic pressure over-
load from AS is characterized by hypertrophic remod-
elling (myocyte hypertrophy and fibrosis) and diastolic 
and systolic dysfunction. In many ways, this left ven-
tricular response considerably influences the morbidity 
and the mortality of the disease199,257–260. Future research 
will probably clarify the mechanisms driving the for-
mation of fibrosis in the pressure-overloaded heart 
and will elucidate the abnormal diastolic properties 
(such as stiffness versus relaxation) involved in AS. In 
asymptomatic patients, targeting the adverse remodel-
ling sequelae of the valvular stenosis with a therapeutic 
medical intervention may delay the onset of symptoms 
and may enable the delivery of new valves into healthier 
hearts, thereby potentially improving long-term cardiac 
 performance and functional capacity.
TAVR will be used in lower risk populations
With iterative improvements in transcatheter valves 
and lower procedural complications (less paravalvu-
lar leak, permanent pacemakers, stroke and vascular 
injury), TAVR will probably start to be used in lower 
risk populations (TABLE 4). However, questions about 
valve durability will need to be addressed. Although 
TAVR might become a viable option in patients with 
low risk and isolated AS, there will probably continue 
to be a group of patients for whom surgical AVR is 
preferable because it allows for more optimal treat-
ment of concomitant pathology such as left main 
coronary disease or severe mitral or tricuspid valve dis-
ease. The currently available option of a transcatheter 
valve-in-valve procedure might lead cardiac surgeons 
to implant bioprosthetic valves (rather than mechan-
ical valves) in younger patients, with the understand-
ing that a new  bioprosthetic valve can be subsequently 
implanted using TAVR.
Table 3 | Key management decisions when selecting a technique and prosthetic valve for aortic valve replacement
AVR technique or 
valve type
Indication Contra-indication Advantages Limitations
Surgical AVR • Indication of AVR
• Low to high surgical risk
• Prohibitive surgical risk
• Life expectancy <1 year
• Standard therapy 
with well-established 
record of safety, 
efficacy and durability
• Invasive
Surgical AVR with 
biological valve
• Patient preference
• Achievement of good 
anticoagulation unlikely
• Age >65 years
• Life expectancy <1 year • Does not require 
anticoagulation
• Limited long-term durability
Surgical AVR with 
mechanical valve
• Patient preference
• Patients already on 
anticoagulation
• Life expectancy <1 year
• Contraindication to 
anticoagulation
• Long-term durability • Requires life-time 
anticoagulation (increased risk 
of bleeding)
Transcatheter AVR* • Indication of AVR
• High or prohibitive surgical risk
• Life expectancy <1 year • Less invasive than 
surgical AVR
• Long-term durability unknown;
• Higher risk of paravalvular AR
AR, aortic regurgitation; AVR, aortic valve replacement. *With balloon-expandable or self-expanding valves.
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Table 4 | Completed, ongoing and future clinical trials on different therapeutic procedures and strategies for AS






Design Intervention(s) End points and results Status Refs
PARTNER-IB • Symptomatic 
severe AS
• Inoperable




• 1‑year mortality: 30.7% TAVR versus 
49.7% conservative*
• 1-year mortality or major stroke:  
33% TAVR versus 50.3% conservative*





PARTNER-IA • Symptomatic 
severe AS
• High risk
699 Randomized TAVR (SAPIEN) 
versus SAVR
• 30-day mortality: 3.4% TAVR versus 
6.5% SAVR
• 1‑year mortality: 24.2% TAVR versus 
26.8% SAVR
• 1-year mortality or major stroke:  
26.5% TAVR versus 28% SAVR





PARTNER-IIB • Symptomatic 
severe AS
• Inoperable
560 Randomized TAVR (SAPIEN) 
versus TAVR 
(SAPIEN-XT)
• 30-day mortality: 5.1% SAPIEN versus 
3.5% SAPIEN-XT
• 1‑year mortality: 23.3% SAPIEN versus 
22.3% SAPIEN-XT
• 1-year major stroke: 5.5% SAPIEN 
versus 4.8% SAPIEN-XT
Completed 271
SAPIEN 3-HR • Symptomatic 
severe AS




TAVR (SAPIEN 3) • 30-day mortality: 2.2%
• 30-day major stroke: 0.86%
• 1-year mortality: 14.4%
• 1-year major stroke: 2.4%
Ongoing 272, 
273





TAVR (SAPIEN 3) • 30-day mortality: 1.1%









TAVR (SAPIEN 3) • 1-year mortality: 26%






• Intermediate or 
high risk
750 Randomized TAVR (CoreValve) 
versus SAVR
• 1-year mortality: 19.1% TAVR versus 
14.2% SAVR*
• 1-year major stroke: 22.2% TAVR versus 
28.6% SAVR*
• 2-year mortality: 22.2% TAVR versus 
28.6% SAVR*




CHOICE • Symptomatic 
severe AS
• Low risk
241 Randomized TAVR (SAPIEN-XT) 
versus SAVR 
(CoreValve)
• 30-day mortality: 4.1% TAVR versus 
4.3% SAVR
• 30-day stroke: 5.8% TAVR versus  
2.6% SAVR
Completed 275
NOTION • Symptomatic 
severe AS
• Low risk
280 Randomized TAVR versus SAVR • 1-year mortality: 4.9% TAVR versus  
7.5% SAVR
• 1-year all stoke: 2.9% TAVR versus  
4.6% SAVR
Completed 276
PARTNER-IIA • Symptomatic 
severe AS
• Intermediate risk
2,000 Randomized TAVR (SAPIEN-XT) 
versus SAVR
• Primary end point: 2-year mortality  
or major stroke
Ongoing 277
SURTAVI • Symptomatic 
severe AS
• Intermediate risk
2,500 Randomized TAVR (CoreValve) 
versus SAVR







• Heart failure 
symptoms
600 Randomized Heart failure 
therapy alone 
versus heart failure 
therapy plus TAVR
• Primary end point: hierarchical 
composite of 1-year death, stroke, 












• Primary end point: composite of death, 
stroke, myocardial infarction, heart 
failure hospitalization, left ventricular 
systolic dysfunction and quality of life
Future
AS, aortic stenosis; AVR, aortic valve replacement; LVEF, left ventricular ejection fraction; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve 
replacement.*Difference between groups is statistically significant.
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Improved accuracy of risk prediction for TAVR
Although the STS score and EuroSCORE are reason-
ably accurate in predicting morbidity and mortality 
after TAVR, they were developed in patient cohorts of 
younger individuals with fewer comorbidities undergo-
ing cardiac surgery261. With multiple clinical trials and 
registries collecting detailed data on patients undergo-
ing TAVR, there will be several risk prediction models 
developed specifically in and for TAVR patients that will 
improve upon existing ones. These scores will incor-
porate factors associated with older age (for example, 
frailty, disability and cognitive impairment) and will 
be developed to predict quality of life outcomes, not 
just mortality.
Increased use of biomarkers
Biomarkers have not been widely used in the manage-
ment of patients with AS. Natriuretic peptides, such as 
BNP, are somewhat of an exception, but their role in 
management decisions has not been clearly defined3,4. 
In the coming years, there will be more specific cut-offs 
of natriuretic peptide levels to guide management deci-
sions187. High sensitivity cardiac troponin will be more 
routinely integrated into our evaluation of patients with 
AS194. Increasingly, as in non-AS heart failure popula-
tions, a multimarker approach will be taken to measure 
diverse biological pathways in a more integrated man-
ner to gain insight into ventricular health and systemic 
factors that might affect clinical outcomes and influence 
management strategies regarding valve replacement and 
adjunctive therapies198.
Tailored management strategies for AVR
Treatment decisions will become more personalized 
regarding when, whether and how to carry out valve 
replacement. Previously, management decisions were 
mainly conceptualized in terms of the severity of AS 
and the presence or absence of symptoms. Phenotyping 
and risk stratification has and will become more 
sophisticated, allowing for more nuanced management 
decisions. The left ventricular response to a given degree 
of pressure overload, systemic factors, biomarkers, 
patient symptoms and operative risk will be integrated 
alongside an assessment of AS severity to influence 
 management strategies regarding valve replacement.
In the near future, the realization of randomized trials 
might pave the way for new indications for AVR. The 
trials that should be considered a priority by the cardio-
logy community include early ‘prophylactic’ AVR versus 
a watchful waiting strategy in asymptomatic patients 
with severe AS, and TAVR combined with heart failure 
therapy versus heart failure therapy alone in patients 
with moderate AS, low LVEF and heart failure symptoms 
(TABLE 4). Also, the data from ongoing and future trials 
will help to better individualize the type of AVR accord-
ing to the baseline risk profile of patients. Results from 
some recent studies suggest that TAVR might be prefer-
able to surgical AVR in patients with diabetes, chronic 
obstructive pulmonary disease, pulmonary hypertension, 
small aortic annulus and low-flow, low-gradient AS262–266.
Interventions after AVR to improve clinical outcomes
Given that AS is conceptualized as a mechanical prob-
lem (valve obstruction) in need of a mechanical solution 
(valve replacement), it is common to view the problem 
or disease of AS as ‘fixed or solved’ after the valve is 
replaced, with little attention directed towards strategies 
and interventions that might improve clinical outcomes 
in the post-valve replacement period. We anticipate that 
there will be a growing recognition of factors that impair 
an optimal clinical outcome in patients with AS after 
valve replacement, and that interventions will be iden-
tified that might improve these outcomes. These might 
include interventions such as adjunctive medical thera-
pies (for example, anti-fibrotic and anti-hypertrophic 
agents) to improve left ventricular reverse remodel-
ling and function, or lifestyle interventions to improve 
 outcomes for frail patients undergoing TAVR.
Table 5 | Comparison of TAVR access routes
Approach Indication Contra-indication Advantages Limitations
Transfemoral • Default approach for 
TAVR
• Small, tortuous or calcified 
femoro-iliac arteries
• Least invasive approach • Requires a minimal femoral 
and iliac artery diameter of 
6.0–6.5 mm
Transapical (via 
the chest between 
the ribs)
• Femoral and other 
vascular access not 
possible
• Left ventricular aneurysm 
or thrombus
• Severe pulmonary disease*
• Severe left ventricular 
systolic dysfunction*
• Better control of the 
positioning of the valve
• More invasive
• More myocardial injury
• More respiratory complications
Transaortic (via 
mini-sternotomy)
• Femoral and other 
vascular access not 
possible
• Viable alternative to 
transapical
• Complete porcelain aorta 
(rare)
• Avoids manipulation and 
suturing of left ventricle 
apex with potential of 
causing apical dysfunction
• Requires a non-calcified area on 




• Alternative access routes 
in the context of severe 
peripheral artery disease
• Unsuitable anatomy or size 
of the alternative artery
• Provides an alternative 
to transfemoral that is 
potentially less invasive than 
transapical or transaortic
• Depends on route (carotid 
approach may increase stroke 
risk; transcaval approach may 
have bleeding or damage to the 
aorta that is difficult to control)
TAVR, transcatheter aortic valve replacement. *Relative contra-indication. ‡Left subclavian or axillary artery, carotid artery or transcaval route.
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